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In the investigation on polymer particle in hydrophilic matrix system, 
hydroxypropyl methylcellulose (HPMC) mean particle size of 113 µm 
was identified as critical cut-off criterion for obtaining consistent 
sustained drug release profile. The mechanism of aspirin release from 
matrix tablets was studied. Polymer particles of similar mean particle 
sizes but of different size distributions were found to influence drug 
release rate but not the release mechanism. Drug release constant was 
found to be proportionally related to polymer mean particle size and 
relative number of polymer particles in the matrix system. This 
relationship could help to predict drug release performance from matrix 
systems with varying polymer content and particle sizes. 
 
In reservoir dispersed matrix tablets, the release performances of 
water-soluble naproxen sodium and sparingly soluble aspirin from 
ethylcellulose (EC) coated HPMC matrix tablets were investigated. 
Drug release decreased as HPMC content in the core increased. Higher 
EC coating load led to lower drug release rate. Increase of Opadry 
(HPMC based coating system) concentration in EC coat increased drug 
release rate. Release profile of aspirin was more sensitive to EC 
coating level while that of naproxen sodium was influenced more 
significantly by HPMC content in the core. Impact  of EC coat and 
Opadry on drug release kinetics were dependent on EC layer thickness. 
Release kinetics generally followed the zero order model at higher EC 
coating levels. At low EC coating level,  an increase of Opadry ratio in 
v 
 the EC coat modified the drug release kinetics to first order. The zero 
order release constants of naproxen sodium tablets coated with 
different EC coating formulations and at different coating levels 
showed a linear relationship with HPMC contents in the core. This 
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The oral route is the most convenient and commonly employed route for 
drug administration. In order to achieve and maintain the drug 
concentration within a therapeutically effective range, i t  is often 
necessary to consume a normal release drug dosage form several t imes a 
day at regular intervals. Besides the inconvenience, this also results in 
significant fluctuations of the plasma drug level.  The development of 
extended release systems provides an ideal approach to deliver drug at a 
desired rate and maintain consistent /  constant drug concentration over an 
extended period of time. Benefits of extended release systems that arise 
from the stable plasma drug level improve therapeutic efficacy and reduce 
side effects.  
 
The term “extended release” implies a predictability and reproducibility 
in the drug release rate and kinetics. There is an extensive number of 
approaches available to achieve the above goals. The most often-used 
control methods employ monolithic or reservoir–type devices. For a 
monolithic device, the active ingredient is homogeneously dispersed in 
the rate-controlling polymer which forms either a lipophilic or 
hydrophilic matrix system where the release kinetics are governed by 
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 diffusion or a combination of erosion and diffusion mechanisms. Polymers 
used for monolithic matrix systems include hydroxypropyl 
methylcellulose, ethylcellulose, chitosan and chitin. In the reservoir 
devices, the active drug and other ingredients are enclosed in a water-
insoluble membrane formed by film coating. The rate-controlling 
membrane can be classified into two types: homogeneous and 
microporous. 
 




Hydrophilic matrix systems for extended release provide many 
advantages. Firstly, the matrix system is relatively easy to formulate.  
Secondly, production of the dosage form can use existing and 
conventional equipment and processing methods. In addition, the matrix 
system is economical,  can be produced using a wide range of polymers, 
and is able to support high drug dose levels (Alderman, 1984 and Dabbagh 
et al . ,  1996). It  is also less affected by variations in ingredients, 
production methods and end-use conditions than many other extended 
release systems, thus resulting in more uniform release profiles and high 
resistance to dose dumping (Ho et al. ,  1997 and Jovanovic et al. ,  1997). 
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 2. Hydroxypropyl methylcellulose 
 
The most popular polymer available for use in hydrophilic matrix systems 
is hypromellose, also known chemically as hydroxypropyl methylcellulose 
(HPMC). HPMC is a propylene glycol ether of methylcellulose, and 
therefore has a polymeric backbone of cellulose, a natural carbohydrate 
that contains repeating units of anhydroglucose. During the manufacturing 
process, cellulose fibers are first  treated with caustic soda, followed by 
methyl chloride and/or propylene oxide. The end product obtained is then 
purified and ground to a fine powder.  
 
There is a wide range of HPMC of different molecular weights and 
degrees of substitution.  Being a semi-synthetic material derived from 
cellulose, the degree of HPMC polymerization can be varied during 
manufacture to provide a polymer with a range of desirable properties.  
The viscosity of HPMC is controlled by molecular weight. The ratio of the 
methoxyl (-OCH3) and hydroxypropoxyl (-OCH2CHOHCH3) substituents 
influences the properties of the polymer such as organic solvent 
solubility, thermal gelation temperature of the aqueous solution and rate 
of hydration.  The three major types of commercial HPMC classified 
according to the amount of methoxyl and hydroxypropoxyl substitutions 
in the polymer are listed as follows:  
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 Type                 % methoxyl    % hydroxypropoxyl 
 
HPMC 2208 USP (Methocel K) 19-24    7-12 
HPMC 2910 USP (Methocel E)  28-30    7-12 
HPMC 2906 USP (Methocel F)   27-30    4-7.5 
 
Methocel K has the fastest hydration rate, followed by Methocel E and 
Methocel F. Another major difference in the physical properties of these 3 
types of HPMC is their cloud point.  At temperatures below the cloud point, 
the polymer absorbs a large amount of water and gels rapidly. Above the 
cloud point, the polymer does not take up water.  There is a gradual 
transition as the cloud point is approached, with the polymer losing more 
and more water of hydration and the speed of gelation in a hydrating 
matrix decreases (Mitchell  et  al . ,  1990).  
 
HPMC is a widely accepted pharmaceutical excipient and is included in 
all  major pharmaceutical compendia. It has a good safety record with low 
toxic effects and is also compatible with most drug substances.   
 
3.  Controlled release mechanisms 
 
The mechanisms of extended release action of HPMC matrices are 
complex because the micro- and macro- structures of HPMC when 
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 exposed to water are strongly time–dependent. To achieve extended 
release properties, it  is essential that the chosen type of HPMC provides 
rapid hydration on contact with the dissolution medium, allowing the 
HPMC polymer chains to start to swell and form a continuous, gelatinous 
layer. This rapid formation of gel layer prevents fast penetration of water 
into the tablet core and tablet disintegration, which would otherwise 
occur. The viscous layer has another important role. It  retards the rate of 
drug diffusion through the matrix to the exterior. The rate of erosion of 
the gel layer controls the rate of liberation of any insoluble active 
substance, which cannot be released by diffusion. Fast polymer hydration 
and gel layer formation are particularly critical when formulating with 
water-soluble drugs and water-soluble excipients (Mitchell et al. ,  1993b, 
Mitchell  et al. ,  1993c and Ford et al. ,  1985a). 
 
A swollen HPMC matrix can be divided into four components: dry glassy 
core, swollen glassy layer, gel layer and diffusion layer separating the 
matrix from the external medium. Within the dry glassy core, the polymer 
takes up most of the space, producing a completely unhydrated region. In 
the swollen glassy layer, solvent diffusion results in a small increase in 
water concentration, resulting in a more mobile network with very strong 
polymer chain entanglement. In the gel layer, due to the significant 
swelling that occurs, polymer concentration is lower than in the dry 
glassy and swollen glassy layers but strong chain entanglement is still  
5 
 maintained. Finally, in the water rich diffusion layer, the polymer 
concentration is so low that chain entanglement becomes weak. 
 
Gel strength is affected by type, viscosity and concentration of polymer 
employed. In general,  the strength of the gel increases with increasing 
molecular weight,  via the effect of polymer viscosity.  
 
As HPMC is water soluble, the polymer matrix will gradually dissolve in 
water. Water penetrates the matrix and hydrates the polymer chains, 
which eventually detach from each other and disentangle from the matrix 
into the bulk solution, permitting erosion of the matrix to occur. It  was 
proposed that surface erosion of the matrix is governed by two steps. The 
first step involves just the surface and depends on the rate of hydration.  
The second step involves the transport of polymer molecules from the 
surface across the aqueous diffusion layer, adjacent to the matrix and into 
the bulk solution (Reynolds et al. ,  1998).  
 
Much research work has been done to model the erosion and diffusion 
mechanisms of swellable polymeric matrices. Attempts to separate the 
diffusional and erosional contributions to drug release have been reported.  
In one study, a linear correlation between drug release due to erosion and 
time was observed (Reynolds et al. ,  1998). The diffusional release rate 
6 
 was a function of the molecular weight of the polymer, indicating that 
polymer erosion is dependent on polymer viscosity (Leszek ,  1987).  
 
Mathematical modeling has also been employed to describe the diffusion 
of a penetrant and a solute in a swellable polymer slab (Siepmann et al. ,  
1998). According to the mathematical model,  Equations 1 & 2, used to 
describe the mass transfer processes in the three component system, 
drug/polymer/water, the diffusion coefficients were strongly dependent on 
the concentration of water in the system. Hence, the free volume available 
for diffusion was a function of the water concentration. 
 
D1 = D1 e q exp(-β1(1-c1/c1 e q))         (1) 
D2 = D2 e q exp(-β2(1-c1/c1 e q))        (2) 
 
where D1 and D2  are the diffusion coefficients for water and drug,  β1  and 
β2  are dimensionless constants,  c1  is  the water concentration and c1 e q  is 
the water concentration at the equilibrium state. D1 eq  and D2 eq  are the 
respective diffusion coefficients of water and drug in the equilibrium 
swollen state of the system. 
 
A semi-empirical equation (Equation 3) has been developed for the 
diffusion coefficient,  Dp ,  of polymer within the diffusion layer adjacent to 
a matrix undergoing swelling and dissolution (Ju et al. ,  1997). This 
7 
 equation was a key element in describing the swelling and dissolution of 
the polymer and the release of drug.  For HPMC, Dp  can be related to 
molecular weight, M ,  and polymer concentration. The parameter, Cp ,  
defined as the polymer disentanglement concentration or the polymer 
concentration at the tablet diffusion layer interface, was found to be a key 
parameter in the mathematical model.  
 
Dp = 7.24 * 10- 5 M- 0 . 6  [1 + 700 (M/96000)0 . 7  Cp/8] - 2                (3) 
 
4. Influence of experimental parameters on drug release from HPMC            
matrix systems 
   
During the formulation process of hydrophilic matrix tablets, the 
following factors must be taken into consideration. 
 
a. Polymer content 
 
The content of HPMC in the matrix had considerable impact on drug 
release rate (Baveja et al. ,  1988). Dissolution rate of ibuprofen decreased 
as HPMC content increased in the formula (Wan et al . ,  1991). When 
adinazolam mesylate was used as a model drug, researchers found that 
varying HPMC ratio produced a wide range of drug release curves (Sung 
et al. ,  1996). Low concentrations of HPMC led to tablet disintegration due 
8 
 to lack of sufficient polymer in the system to form a uniform, continuous 
gel layer of appropriate strength.  
 
b. Incorporation of other polymeric excipients 
 
Combining different polymers with HPMC had been found to affect drug 
release mechanism and profile (Perez-Marcos et al . ,  1994 and Baveja et 
al. ,  1988). Mixing Carbopol with HPMC resulted in a decrease in the 
cloud point but increase in water content of the resultant gel,  leading to 
reduction of viscosity. Incorporation of sodium carboxymethyl cellulose 
(NaCMC) into an HPMC matrix converted the release mechanism of 
oxprenolol hydrochloride and propranolol to zero order from non-linear 
release models. This phenomenon was ascribed to the difference in 
erosion rates of NaCMC and HPMC. Other investigations suggested that 
NaCMC is an ionic polymer that could retard the release of oppositely 
charged drugs, but the effect was not found to be dramatic. HPMC 
combined with non-ionic polymers, such as PEG 6000 and ethylcellulose 
was no more effective than the HPMC polymer itself in controlling the 
release rate of chlorpheniramine maleate from polymer matrices.  
 
c. Polymer/ drug ratio 
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 In a study on the release of propranolol hydrochloride and aminophylline 
from HPMC matrices, the drug /  polymer ratio was found to be the major 
factor controlling the drug release. Similar release rates were obtained 
using Methocel K with viscosities of 4,000, 15,000 and 100,000 cp at the 
same drug: HPMC ratio (Ford et al. ,  1985a). 
 
In another study, the diffusion rates for soluble drugs through HPMC gels 
were found to be dependent on the gel concentration. This was attributed 
to increased gel tortuosity with increasing concentration of polymer. Drug 
diffusion was however independent of the polymer molecular weight. 
Using propranolol hydrochloride, drug release from the matrix increased 
with increasing drug concentration. (Mitchell  et  al . ,1993c).  
 
d. Polymer viscosity 
 
Change of polymer viscosity will affect drug release to some degree.  
Much research work was directed at exploring the relationship between 
polymer viscosity and drug release. Using propranolol hydrochloride as 
the model drug, it  was observed that the square of dissolution T5 0 % varied 
proportionately with the solution viscosity (Wan et al . ,  1995). The release 
of acetazolamide from an HPMC matrix became slower when HPMC K4M 
(4,000 cp) was replaced with K15M (15,000 cp) (Dortung and Gunal, 
1997). In one study, matrices were produced from 10 % HPMC having 
10 
 viscosity values of 15, 860, 5000, 20,000 and 30,000 cp. A linear 
relationship between the reciprocal of release rate and the HPMC 
viscosity was observed. When the HPMC content was increased above 20 
%, drug release was independent of viscosity (Campos-Aldrete and 
Villafuete-Robles, 1997).  
 
e. Polymer particle size 
 
Particle size can greatly influence polymer performance in the hydrophilic 
matrix systems (Mitchell et al. ,  1993a).  In the study of the dissolution 
rate of propranolol hydrochloride from matrices containing different size 
fractions of HPMC K15M, it  was found that the release rate decreased as 
the polymer particle size was reduced from > 355 µm to 150 - 210 µm. 
Further reduction in polymer particle size to 75 - 150 µm and < 75 µm 
caused no noticeable decrease in dissolution. Initial  “burst” release of 
drug was seen at the highest level of polymer particle size > 355 µm and 
low content of HPMC. 
 
The dissolution rate of metronidazole from matrix tablets containing 10 % 
HPMC exhibited a linear relationship with the cube of the diameter of the 
HPMC particles.  When the HPMC concentration was increased to 20 % 
and above, release rate was not affected by the polymer particle size. An 
increasing burst effect occurred with increasing particle sizes of HPMC. 
11 
 The particle size fractions of the HPMC used in the experiment were 163, 
213, 335 and 505 µm respectively (Campos-Aldrete and Villafuete-
Robles, 1997). 
 
f.  Drug solubility and type 
 
Higher drug solubility generally result  in faster release rates, due to the 
generation of higher diffusional driving forces. The effects of propranolol 
hydrochloride, tetracycline hydrochloride and indomethacin on the 
properties of gels and swelling characteristics of matrices containing 
HPMC had been evaluated. It  was found that tetracycline hydrochloride 
and propranolol hydrochloride increased the cloud point of HPMC K15M 
(Mitchell  et  al . ,  1990). Tetracycline hydrochloride also interfered with the 
hydration process of HPMC on contact with water.  Thermal analysis 
showed that propranolol hydrochloride affected the equilibrium water / 
HPMC content in HPMC gels. Water-soluble drugs also had an effect on 
the extent of gel swelling (Mitchell  et  al . ,  1993b). 
 
g. Drug particle size 
 
Impact of drug particle size on drug release from HPMC matrix systems 
varied according to drug type and polymer content level.  It  was reported 
that differences in drug particle size generally had little effect on drug 
12 
 release rate when potassium chloride and promethazine hydrochloride 
were used as model drugs in HPMC matrices (Ford et al. ,  1985b). It  was 
found that only at low HPMC: drug ratios, an appreciable effect was seen 
at a very large mean drug particle size.  This was explained by the 
tendency of the matrix to be very “loose” and to disintegrate rapidly 




Addition of surfactants may affect drug release from a matrix system. It  
was observed that anionic surfactants could retard the release of cationic 
drugs such as chlorpheniramine maleate from extended release matrix 
tablets (Khan and Zhu, 1998 and Liam and Stanley, 1988). Sodium 
dodecyl sulphate, an anionic surfactant, was found to retard the release of 
propranolol hydrochloride (Ford et al. ,  1991).  
 
The influence of ionic surfactants on drug release is concentration-
dependent. The mechanism of this effect is via an ionic interaction 
between drug and surfactant.   The ability of ionic surfactants to retard the 
release of drugs from HPMC matrices had been studied (Liam and 
Stanley, 1988). The concentration of surfactant within a matrix was 
reported to be an important parameter affecting release rate.  The 
hydrocarbon chain length of surfactant did not appear to be a major factor 
13 
 influencing drug release rate.  It  was found that the surfactant only had an 
effect when both it  and the drug were ionized and had opposite charges. It 
was postulated that such complexes formed in situ  within the HPMC 
matrix and that drug release from these systems would rely principally 
upon erosion (Liam and Stanley, 1998). 
 
i .  Filler solubility 
 
The effects of the fil ler on drug release are dependent on the drug 
substance, polymer level and level of filler itself in a matrix system. 
Some researchers had indicated that theophylline release rate from matrix 
tablets was not affected by a switch between a soluble filler such as 
lactose and an insoluble fil ler such as tricalcium phosphate.  (Veiga et al . ,  
1997).  Conversely, in the case of the model drug metoprolol tartrate, i t  
was demonstrated that drug release rate increased when the filler was 
changed from dibasic calcium phosphate to lactose. Some experiments 
also indicated that the release of morphine from HPMC matrices was 
affected by the addition of lactose, which caused a concentration-
dependent increase in the drug release rate (Bosca et al. ,  1995) 
 
j.  Production method and parameters 
 
14 
 Production of matrix systems as a dosage form normally involves wet 
granulation or direct compression processes. Therefore, i t is important to 
study the influence of production methods and parameters,  such as mixing 
time of the ingredients and compression force on drug release behavior. 
The effect of compression force and subsequent tablet hardness on drug 
release was evaluated using a freely soluble drug centperazine and a 
polymer combination of HPMC and NaCMC. It was found that drug 
release was independent of tablet hardness in the range from 4 to 12 
kg.cm- 2 (Baveja et al. ,  1998). In the evaluation of  the effect of lubricant 
mixing time on extended release matrix tablets,  i t  was found that drug 
release rate was only slightly affected by the duration of mixing (Sheskey 
et al. ,  1995).  
 
k. Tablet dimension and shape  
 
Standard convex and capsule-shaped tablets were used to examine the 
effect of tablet size and shape (Siepmann et al. ,  2000).  It  was found that 
the larger the surface area, the faster was the release rate. Control of 
surface area-to-volume ratio offered an effective means of achieving the 
required release rates for different dose-sizes of the same formulation. 
Propranolol hydrochloride and chlorpheniramine maleate were used as 
model drugs. The effect of the initial matrix radius on release rate was 
found to be more pronounced than the effect of the initial thickness. 
15 
 Research work also found that tablet shape significantly affected the rate 
of release of theophylline from matrix tablets (Veiga et al. ,  1997). 
 
l .  Dissolution medium  
 
The dissolution medium employed may also affect drug release. It  was 
found that addition of sodium or potassium chloride to the dissolution 
medium decreased the solubili ty of diclofenac sodium, with a resultant 
reduction in dissolution of the drug from an HPMC matrix system 
(Kurahashi et  al. ,  1996). The effect of sodium chloride was greater than 
potassium chloride. Dissolution rate of the drug was also studied in a 
medium that simulated the changing pH of the pathway followed by the 
drug as it  passed from the stomach to intestine (Perez-Marcos et al . ,  1994). 
Dissolution rate was found to be inversely related to the rate at  which the 
pH was changed. This could be due to the deposition of an insoluble drug 
layer on contact with the acid medium. Increasing the viscosity of the 
HPMC used resulted in slower release rates.   
 
5. Studies on the effects of HPMC particle properties 
 
Matrices composed of propranolol hydrochloride and coarse particles (200 
to 300 µm) of Methocel K exhibited premature drug release (Dabbagh et 
al. ,  1996 and Mitchell et  al. ,  1993a). The release rate decreased as 
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 polymer particle size was decreased. Coarse polymer particles above a 
critical size tended to result in failure of the matrix system, which was 
characterized by rapid matrix disintegration and immediate release of the 
drug. It  was also found that polymer particle size had a greater influence 
on the dissolution of soluble drugs which require very rapid formation of 
a strong gel layer (Dabbagh et al. ,  1996). 
 
HPMC particle size has been reported to affect the rate of dissolution of 
drug from a matrix tablet (Campos-Aldrete and Villafuete-Robles, 1997). 
Some authors had attributed this to the difference in water uptake and 
hydration rate between different particle size fractions. Rapid dissolution 
rates brought about by coarse fractions of HPMC were considered to be 
due to slow hydration of the polymer, allowing disintegration of the tablet 
before complete hydration of the external layers had occurred. It was 
considered that small size fractions of HPMC allowed more rapid and 
uniform hydration of the surface of the matrix, thereby effectively 
retarding release. 
 
In contrast, some experimental results demonstrated that contrary to 
hydrating slowly, coarse particles bound water faster than finer particles 
(Mitchell et al. ,  1993a). After 60 minutes, bound water levels for coarse 
and fine particles were similar.  However, it  was the first few minutes of 
hydration that were the most important, corresponding to the period when 
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 a protective gel coat was formed around the matrix. Hence, the 
differences in release rates should not be considered to be due to 
differences in the rates of hydration between the different particle size 
fractions of the polymer.  
 
The effect of variations in drug release rate with varying polymer particle 
size was attributed to differences in surface area or differences in porosity 
of the controlled release gel layers.  HPMC polymer fractions of smaller 
mean particle sizes had greater surface area to weight ratios than fractions 
of larger mean particle size. The greater surface area enhanced contact 
between polymer and water,  thus increasing the overall  rate at  which 
polymer hydration and gelation occurred.  This led to more effective 
formation of the protective gel barrier that was critical to the performance 
of hydrophilic matrix tablets (Campos-Aldrete and Villafuete-Robles, 
1997). 
 
There is l imited information on the influence of HPMC particle size on 
drug release from matrix systems.  It  is therefore important and 
interesting to study this parameter in greater detail .   Since raw material 
particle properties often vary from batch-to-batch, a full  understanding of 
the variations caused by particle size and the mechanisms involved in 
these variations, is considered to be of practical usefulness. 
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 6. Measurement of particle properties of HPMC powder 
 
The determination and control of particle size is often a necessity in 
pharmaceutical analysis and formulations. This is particularly true in 
solid dosage forms. The size range and distribution of particles in a given 
product can influence its safety, efficacy, stability and viability of the 
manufacturing process (Randall,  1995). 
 
In describing the particle diameter of a sample, three size parameters may 
be used: mean, median and mode. The mean is the sum of all  diameters 
divided by the total number of particles. The median is the value above 
and below which 50% of the particles are found. The mode represents the 
size occurring most frequently.  The mode is used less frequently than 
either mean or median. In a perfectly symmetrical distribution, mean, 
median and mode values are the same (Randall,  1995 and Weiner and 
Tscharnuter, 1987). Since most pharmaceutical substances comprise a 
range of particle sizes, it  is important that the size distribution is 
determined.  
 
A variety of techniques is available for sizing particles. The following 
methods are the most frequently used to characterize powders (Weiner and 
Tscharnuter,  1987 and Allen, 1990). 
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 a.  Microscopy   
 
Despite the emergence of many methods for particle sizing, microscopy 
still  remains a powerful tool. Advantages include direct visual 
representation of the particle being measured and the provision of 
information on particle shape. Only small samples are needed and the 
equipment is relatively inexpensive and simple to calibrate and maintain.  
 
b. Sieving  
 
Sieves provide mechanical barriers allowing separation of particles on the 
basis of size. Sieving is a rapid, convenient means of sizing larger 
particles in the dry state. In practice, a series of sieves is mounted with 
the largest mesh on top, followed by successively finer ones and finally a 
collecting pan. By placing a known amount of sample on the top sieve, 
shaking for a defined time, then collecting and weighing the material 
retained by each sieve and the collecting pan, the distribution of particles 
by size in the batch can be determined. 
 
c. Electro-zone sensing 
 
In such systems, sample particles are first suspended in an electrically 
conducting medium. The suspension containing the particles of interest 
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 flows through a small orifice or aperture with an electrode on either side. 
The base resistance to the current between the electrodes is determined by 
aperture size and electrolyte strength. As each sample particle passes 
through the aperture, i t  displaces a volume of electrolyte solution equal to 
its own volume, momentarily changing the resistance and creating an 
electrical pulse. The magnitude of the electrical pulse is directly related 
to the size of the particle. This enables the particles to be sized and 
counted. 
 
d. Light diffraction  
 
This method is based on the theory of Fraunhofer diffraction, static light 
scattering or low-angle forward light scattering. This method can be 
applied to very small particles, as long as their dimensions are larger than 
the wavelength of the incoming light. Like microscopy and electro-zone 
sensing, i t   can be applied to the measurement of a wide range of particle 
types. 
 
7. Particle size, size distribution and number of polymer particles 
 
Particle size and size distribution are important physical properties of a 
polymer powder. Feret’s,  Martin’s, projected area, specific surface, 
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 stoke’s and volume diameters are the various measurements that have 
been used to quantify particle size and size distribution. 
 
Span of size distribution is an indication of the particle size spread 
between the 10% (D1 0 %) and 90% (D9 0 %) points of the cumulative 
distribution, scaled by the size of the 50% (D50 %) point. It  is described by 
the following equation: 
 
Span = (D9 0 % - D1 0 %)/ D5 0 %                              (4) 
 
In light diffraction measurement, the volume of particles in a particular 
size fraction with respect to the total volume of particles measured could 
be determined. The number of particles in the size fraction, which was 
referred to as the relative number of polymer particles, can be calculated 
using the following equation: 
 
Np o l y m e r   =   Σ  6 Vi/π  d i 3        (5) 
 
where N p o l y m e r  is the relative number of polymer particles for each size 
fraction, Vi  is the relative volume of polymer particles in channel i  in the 
light diffraction measurement, dI  is  the diameter of the channel i .  
 
C. Reservoir systems – membrane coating 
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 For a reservoir system, the simplest and most effective method to achieve 
extended release is by the use of a membrane coating (Chen and Lee, 
2001). Membrane coating can be carried out by the application of a 
polymer solution or dispersion onto the surface of the dosage form.  As 
the solvent evaporates, polymer solidification occurs in the case of a 
solution or coalescence in the case of a dispersion. In either case, a 
porous membrane is formed and the pores or channels permit drug 
diffusion. Adjustment of the rate of water penetration and drug release is 
achieved by controlling membrane thickness or by addition of soluble 
pore/channel producers (Chen and Lee, 2001 and Kim et al. ,  2000). 
  
Acrylic or water-insoluble cellulosic polymers have been extensively 
utilized as the film-former for reservoir systems. These may be applied 
from organic solution or preferably from aqueous dispersion. The method 
of application and processing conditions may influence the porosity of the 
coating and consequently the release mechanism (Parikh et al . ,  1993 and 
Narisawa et al . ,  1994b). Cellulose esters such as acetates and butyrates 
are often applied to produce insoluble but semi-permeable films. Some of 
the methacrylate polyester polymers are essentially insoluble throughout 
the gastrointestinal tract and may be useful in forming the membrane for 
enveloping reservoir systems.  
 
1. Advantages of ethylcellulose (EC)  
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  Among the film-formers used in pharmaceutical coating, ethylcellulose 
(EC) is probably the most widely used water-insoluble polymer (Narisawa 
et al. ,  1994a and Yang et al. ,  1992). EC is a cellulose ether produced by 
the reaction of ethyl chloride with an appropriate alkaline solution of 
cellulose. EC is an ideal polymer for extended release coating. It  is 
odorless and tasteless, with good film-forming properties. The films 
formed are physicochemically and mechanically stable. The water channel 
within an EC membrane is the major pathway for drug diffusion (Narisawa 
et al. ,  1993 and Wesseling and Bodmeier,  1999).  
 
2. EC coating  
 
There are two methods to apply an ethylcellulose film.  One method uses 
an organic solvent such as ethanol in which EC is soluble.  An alternative 
method uses a plasticised aqueous dispersion system. The latter method is 
preferred due to safety and environmental pollution considerations as well 
as the ability to achieve high level of suspended solids without increasing 
the viscosity of the spray medium. 
  
a. EC film formation 
 
Ethylcellulose film formation from organic solutions occurs when 
evaporation of the solvent initiates an increase in polymer concentration. 
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 At higher polymer concentrations, an intermediate gel-like stage is 
reached. Upon further evaporation of the solvent, a polymeric film is 
obtained (Ozturk et al. ,  1990). 
 
Film formation from aqueous colloidal polymer dispersions is more 
complex (Antal et al. ,  1997). During coating, the polymer dispersion is  
sprayed onto solid particles in suitable equipment under process 
conditions which result in evaporation of water. As water evaporates,  the 
colloidal particles are forced to move closer together to form a packed 
particulate film. Plasticisers are used to reduce the minimum film 
formation temperature (MFT) below the coating temperature.  The 
combination of the close-packing of polymer particles and plasticity from 
operation above the MFT results in polymer coalescence and the 
establishment of a continuous film with suitable permeability to control 
drug release.  
 
The choice and level of plasticiser are critical.  A plasticiser promotes 
coalescence by reduction of the polymer glass transition temperature and 
thus MFT. Under-plasticisation of the polymer can result in incomplete 
film coalescence, while over-plasticisation can produce excessive 
tackiness (Kojima and Nakagami, 2002). The coalescence process, which 
may not be immediate, is dependent on the degree of plasticisation and 
the process temperature.  In cases where coalescence is not immediate, a 
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 post-coating curing process at  elevated temperature is commonly 
recommended to ensure that a coherent stable film is formed. 
 
The pore formation process of EC in the casting process has been 
investigated (Narisawa et al. ,  1993). Where an EC-ethanol–water ternary 
mixture was cast,  a porous film was spontaneously formed via the process 
of coacervation and gelation of the polymer. Visual and microscopic 
observation revealed that pore formation proceeded on the basis of a 
phase separation mechanism, in which ethanol and water acted as solvent 
and non-solvent, respectively, for the polymer. The concentration of the 
solvents decreased gradually through evaporation. Gelation, which is an 
important process for establishment of the density of the resultant fi lm, 
occurred when the decreasing ethanol concentration reached a critical 
concentration of approximately 62%. This value was almost constant, 
irrespective of polymer concentration and molecular weight. The density 
of the porous EC film was found to be affected by coating solution 
formulation variables, such as organic solvent :  polymer ratio and organic 
solvent species. The permeation study of porous EC film was conducted 
using salicylic acid as the permeant.    
 
b. Permeability enhancement  
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 A coating composed of EC alone may provide excessive retardation of 
release with poorly water-soluble drugs, because of its dense structure, 
small degree of swelling (<4 % weight for pure polymer) and low water 
permeability (Sadeghi et al. ,  2001). In some circumstances, i t  is desirable 
to increase the permeability of an EC film and various microporous film-
coating methods have been developed to achieve this.  Some research work 
has demonstrated that it  is possible to modify the porosity of the EC free 
film by varying the solvent /  polymer ratio. It  was reported that the use of 
different ratios of water and ethanol could control the permeability of EC 
films (Narisawa et al. ,  1993). The most frequently used method of 
permeability enhancement is by the incorporation of water-soluble 
ingredients into the coating dispersion (Yang et al. ,  1992 and Sadeghi et 
al. ,  2001). The inclusion of a hydrophilic polymer in EC coating film may 
increase the degree of swelling of the membrane so that drug permeation 
rate can be modified. In addition, a more swellable coating film may 
reduce the stress from the swollen core so that breakage of the coating 
film can be prevented even if some small flaws or cracks are present. 
Addition of a secondary polymer such as HPMC or polyethylene glycol 
(PEG) increases the hydrophilicity of the film and introduces pore and 
channel structures, thus promoting drug diffusion. Additives such as Span 
20 may act as a carrier for salicylic acid through EC film. 
Tetrabutylammonium bromide may complex with salicylic acid, increasing 
its solubility in the membrane or increasing the diffusion coefficient. In 
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 general, low viscosity methylcellulose (MC), HPMC, 
hydroxypropylcellulose (HPC) and PEG are commonly used additives in 
EC films.  
 
Adding pore-forming agents to EC, to create more porous films, also has 
several other advantages (Narisawa et al. ,  1994c and Kim et al. ,  2000). 
Firstly, i t  reduces film tackiness, making application much easier. 
Secondly, for non-water soluble drugs, this pore forming agent enables an 
increased film-thickness, while achieving the same release rate, thus 
ensuring the relative uniformity of thickness of the applied film and 
reducing variation in dissolution performance.  
 
c. Drug release mechanism  
 
Several mechanisms have been proposed to explain the release behavior 
from EC film-coated systems (Chen and Lee, 2001; Narisawa et al. ,  1994c; 
Sajeev and Saha, 2001; Narisawa et al. ,  1993). One of the mechanisms 
involves the diffusion of solute molecules through the continuous 
plasticised polymer phase. This mechanism assumes that the polymer 
forms a continuous phase in which the plasticiser and other additives are 
homogeneously dispersed and the diffusion of solute molecules within the 
amorphous polymer phase is a dynamic process involving the cooperative 
movements of the penetrant through the polymer chain segments.  In 
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 effect,  thermal fluctuations of chain segments allow sufficient local 
separation of adjacent chains to permit the passage of the penetrant.  It  is 
by this stepwise process that hindered molecular diffusion occurs. This 
behaviour has been described by the following mathematical equation: 
 
Pa = Pm + Pp  = ( Dє /τβ) K  + єp  Dp  /τp                 (6)  
 
where Pa is the drug permeability through the coated tablet,  Pm and  Pp  
are the permeabilities in the polymer and aqueous phase respectively, D  is  
the molecular diffusivity of drug, K  is the distribution coefficient of drug 
between polymer membrane and water, τ  is the tortuosity factor,  є  is the 
volume fraction of polymer channels and β  is the chain immobilization 
factor, reflecting the degree of cross-linking of crystallites in the polymer, 
Dp  is  the aqueous diffusivity of drug, єp is the volume fraction of aqueous 
channels, and τp  is the tortuosity of the aqueous channels (Ozturk et al. ,  
1990).  
 
It  was recognized that an osmotic pump mechanism also plays an 
important part in drug release from EC-coated systems. This has been 
demonstrated using coated spherical beads. Phenylpropanolamine 
hydrochloride (PPA) was used as a model drug. A plot of release rate 
against osmotic pressure revealed an inverse linear relationship with a 
non-zero intercept. The steep dependency of release rate on osmotic 
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 pressure of the medium suggested that osmotically-driven release is a 
major mechanism for PPA pellets coated with an EC based film, while the 
non-zero intercept indicated some contribution from the diffusion 
mechanisms. A mathematical equation was derived to represent 
osmotically driven release: 
 
J = α∆Π( Ci-Cb) = k σ∆Π(Ci-Cb)            (7) 
 
where α  equals the product of k and σ ,  and is the osmotic driving force 
parameter, J is the flux of the solute (permeation rate per unit surface 
area) ,  k  is the filtration coefficient,  σ  is the reflection coefficient, ∆Π  is 
the osmotic pressure difference across the coating, and Ci  and Cb  are the 
core and bulk drug concentrations respectively (Ozturk et al. ,  1990). 
 
D. Reservoir dispersed matrix system 
 
Coating of tablets to achieve extended release properties can pose dosing 
problems, as cracks or non-uniformity of the coat can be detrimental to  
drug release, resulting in dose-dumping should the coat fail .  A 
combination of matrix and coating, described as a reservoir dispersed 
matrix system, minimises this problem and gives greater flexibility in the 
achievement of the desired release kinetics and release rate (Sajeev and 
Saha, 2001). Reservoir dispersed matrix systems are composed of a 
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 matrix-type core with a polymer coating having lower permeability than 
the core matrix. The coat serves as a rate-limiting barrier to drug release. 
The available factors for controlling of drug release include drug/polymer 
ratio of the core matrix tablet,  thickness of coating applied to tablet and 
quantity and type of soluble additive present in the coating formulation. 
Such formulations exhibited dual control,  where membrane coating 
controlled the release rate for the initial 3-4 hours of release and matrix 
structure controlled the release during the later phase. There had been 
very limited reported research work on the reservoir dispersed matrix 
systems and the release mechanism from such systems warrant further 
investigation.  
 
1. Pre-plasticized EC dispersion 
 
Aqueous EC dispersion systems had been reported to pose problems when 
used for extended release systems. Changes in drug release profile during 
storage or aging effects had been reported (Wesseling and Bodmeier, 1999 
and  Kojima and Nakagami, 2002). Aging effects had been attributed to 
incomplete coalescence during manufacture, followed by progressive 
coalescence of the colloidal polymer particles during storage. Drug 
release rate generally decreased upon storage. Each EC particle was 
composed of numerous polymer molecules or chains. It  was proposed that  
polymer chains in adjacent particles diffuse across the particle 
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 boundaries, resulting in progressive coalescence and disappearance of the 
particle contours. In such cases, a curing step after the coating process is 
recommended to accelerate the film formation process and avoid stability 
problems. The curing step involves thermal treatment at elevated 
temperatures above the MFT (Kojima and Nakagami, 2002). 
 
Surelease (Colorcon, USA) is an example of an EC dispersion available 
commercially for film coating. It  is a ready-to-use, plasticised and 
stabilised aqueous dispersion of EC. In film formation using pre-
plasticised EC aqueous dispersions, the aging effect can be eliminated 
because complete coalescence of the film is achieved during the coating 
process. In addition, the curing step is not necessary (Sadeghi et al. ,  
2001).    
 
2. Equipment for coating application 
 
Various types of equipment are employed for coating tablets, pellets and 
granules. In the selection of equipment, major considerations are given to 
the following factors. Efficient drying capacity, even distribution of 
coating material inside the coating chamber, effective flow of material to 
be coated without significant attrition, and rapid removal of dust and 
evaporated solvent generated from the coating process. 
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 Commonly used equipment can be broadly divided into 3 categories: 
conventional coating pans, fluid bed coaters and side-vented pans.  
 
The conventional coating pan was originally designed for sugar-coating 
which required low drying air flow volumes. Mixing of the tablet cores is 
generally poor. Without modification to the drying air system and 
improvement in mixing by the use of baffles, problems may arise if this 
type of equipment is used for film-coating. 
 
Fluid bed coaters have high drying and mixing efficiencies. These are 
achieved by high air throughput, blowing from the bottom of coater. 
Fluid-bed coater is mainly used for granule or pellet  coating but is less 
suitable for tablet coating due to attrition problems resulting from the 
intense tumbling action. 
 
Side-vented pans are the most frequently used machine for film coating of 
tablets.  Baffles are added to assist  mixing and ensure even flow of tablets.  
Drying is achieved by air-flow penetrating through the tablet bed and 
coating is applied by spray guns onto the tablet bed surface. An even 
coating spray is achieved by atomising the coating solution to produce a 
dispersion of fine droplets.  
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 E. Mathematical equations used to represent drug release 
kinetics  
 
Different mechanisms of drug release have been proposed for various 
types of extended release product. The drug release mechanisms affect the 
release kinetics, which can be represented by mathematical equations or 
models. Hence, model fitting of drug dissolution results is commonly 
employed to elucidate the drug release mechanism of a product (Wan et 
al. ,  1992;  Gao et al. ,  1996; Veiga et al. ,  1997). The following are 
commonly employed release models.  
 
1.  Korsmeyer-Peppas equation 
 




                                                          (8)  
 
where Mt/M∞   is the fraction of drug released at t ime t ,   K  is a constant 
and n  is the exponent indicative of release mechanism. When n  value is 
approximately 0.5, it  indicates that release follows the Higuchi 
mechanism When n  value is in between 0.5-1, the release mechanism is 
likely to follow first order kinetics. When n  is approaching 1, release 




2.  Zero order equation  
 
    M  = M0  -  K0  t                                                  (9)  
 
where M  is the amount of drug remaining in the product at t ime t ,  M0  is  
the initial amount of drug in the product, and K0  is the zero order release 
constant.  
 
3.  First  order equation  
 
                  (10)  tKLnMLnM 10 −=
 
where K1  is the first  order release constant.  
 
4.  Higuchi square root equation 
 
               (11)  2/1tKM Ht =
 
where Mt  is the amount of drug released at time t  and KH  is the Higuchi 
rate constant.  
 
5.  Hixson-Crowell cube root equation 
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     Mt 1 / 3   = M0 1 / 3  – Kct           (12)  
 





















 II.  OBJECTIVES   
 
The HPMC matrix system provides a convenient approach to sustain drug 
release. However, during formulation, scale-up and routine manufacture, 
i t  is often difficult to achieve reproducibili ty in drug release behaviour. 
One of the critical criteria is the polymer particle size.  Differences in 
polymer particle size may lead to significant variations in drug release.  
In extreme situations, these variations could result  in tablet disintegration 
and consequential dose dumping. Control of HPMC particle size is a 
common approach adopted to achieve batch to batch release consistency. 
In practice, it  is unrealistic to control the HPMC powder to a very narrow 
particle-size range, due to cost and availability concerns.  Our literature 
search has suggested that research on the impact of a wide range of 
polymer particle sizes and quantity of HPMC particles in the formulation 
on drug release profile and kinetics is l imited and worthy of further 
investigation. Hence, the specific aims of the first  part of the study were: 
 
(a).   to investigate the effects of HPMC content (or quantity of HPMC 
particles) on drug release performance, 
 




 (c).   to evaluate the effects of HPMC particle size distribution on drug 
release.  
 
Application of EC coating to matrix tablets is considered to be effective 
in modifying drug release kinetics and is especially useful in achieving 
time-independent extended release performance of the drug delivery 
system. The combination of EC coating and hydrophilic HPMC matrix 
systems is predicted to provide stable extended drug release with much 
reduced danger of dose dumping. In addition, it  also enables greater 
formulation flexibility by provision of a greater number of release 
rate/release kinetics adjustment factors. The available information on this 
type of delivery system, including its mechanism of drug release, is very 
limited. Hence further study could help to provide useful knowledge for 
formulation and production of such sustained release dosage forms. 
 
The aims of the second part of the study were: 
 
(a).   to investigate the release performance of HPMC matrix tablets 
coated with EC, using model drugs of different solubilit ies,   
 
(b).   to evaluate the effects of HPMC content on drug release from EC-
coated  matrix tablets,   
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 (c).   to identify the effects of EC coating weight gain on drug release 
performance, and  
 
(d).  to investigate the effects of varying quantities of soluble additive in 



















 III.  EXPERIMENTAL  
 
Part I.  Study of the effects of polymer particle properties on 
drug release from matrix tablets. 
 
A. Materials  
 
Aspirin (USP grade) was used as a model drug. Solubility of aspirin in 
water is 3 in 100 parts at  20 ºC. Aspirin was micronised using a pin mill  
(Retcsh ZM 1000, Germany) to a mean particle size of 79 µm. Anhydrous 
lactose (Pharmatose DCL 21, DMV, The Netherlands), dibasic calcium 
phosphate (Emcompress, Edward Mendell,  USA) and magnesium stearate 
(Merck, Germany) were used as supplied. 
 
Matrix polymer used was HPMC (K15M premium, 15,000 cps, Dow 
Chemical,  USA). Using sieves, the HPMC powder was divided into the 
following sieve aperture size fractions for study: 20 µm – 30 µm, 40 µm – 
50 µm, 70 µm – 80 µm, 100 µm – 120 µm and 160 µm – 200 µm. Unsieved 




1. Milling of drug 
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 Aspirin was comminuted using a pin mill  (Retsch ZM 100, Germany). For 
the pin-milling process, the screen size selected for use was 500 micron 
with a 24-pin impeller rotating at a speed of 15000 rpm. The batches of 
milled aspirin powder were then combined.  
 
2.  Preparation of matrix tablets 
 
The formulations of the matrix tablets used for evaluating the effects of 
HPMC particle size with fil lers of different solubilities are given in Table 
1-3.  The batch weight of each formulation was 35 g.  Weighed quantities 
of aspirin, HPMC and filler were first thoroughly mixed in a plastic bag 
for 15 min. The lubricant, magnesium stearate, was then added and mixed 
for a further 5 min.  A 350 mg weighed portion of resultant mixture was 
then compressed into tablets of 3.9 mm thickness, using a single punch 
tablet machine (Manesty, E2, UK) with 9.5 mm diameter flat punches. 
Only tablets with weight deviation within 2 % of the theoretical weight 
were selected for study.  The amount of aspirin in each matrix tablet was 
kept at a constant 120 mg, while the concentration of HPMC was varied.  
For the evaluation of polymer particle size effects, 5 different size 
fractions of HPMC were used at each concentration level.  For evaluating 
the effects of filler solubility, unsieved HPMC was used with either 
lactose (soluble fil ler) or dibasic calcium phosphate (insoluble fil ler).  
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 Table 1. Formulations of aspirin matrix tablets for evaluating the effects of 
HPMC particle size  
 
 
                                   





    
    A                     B                     C                      D                      E   




  120 
 
    120 
 
    120 
 
    120 
 




   5%  
 
    10% 
 
    20% 
 
    30% 
 
    40% 
 
Lactose    QS  
 






   1%     1%     1%     1%     1% 
 
* Tablet weight was kept constant at 0.350 g. Five different size fractions 
of HPMC were used at each HPMC concentration level.  QS, as much as 









 Table 2. Formulations of aspirin matrix tablets using unsieved HPMC K15 










   F                 G                H                 I                 J                 K 
          
 
Aspirin (mg) 
   
  120 
     
      120 
    
      120 
    
       120 
     





   
  0%  
     
      10% 
    
      20% 
    
       30% 
     
     40%            50% 
 
Lactose   QS  
 
      QS        QS         QS      QS               QS 
Magnesium 
Stearate 
  1%       1%        1%         1%      1%               1% 
 












Table 3. Formulations of aspirin matrix tablets using unsieved HPMC K15 











   L                 M                N                 O               P                Q 
          
 
Aspirin (mg) 
   
  120 
     
      120 
    
      120 
    
       120 
     





   
  0%  
     
      10% 
    
      20% 
    
       30% 
     
     40%            50% 
 
DCP   QS  
 
      QS        QS         QS      QS               QS 
Magnesium 
Stearate 
  1%       1%        1%         1%      1%               1% 
 










 3. Determination of drug content of matrix tablets 
 
Randomly selected tablets were pulverized individually using a pestle and 
mortar.  About 100 mg of the resultant powder was accurately weighed and 
transferred to a 250 ml volumetric flask. Phosphate buffer,  pH 6.8 (USP) 
was added with continuous agitation to final volume. An aliquot sample 
was removed through a 0.45 µm filter and assayed for aspirin 
spectrophotometrically at 265 nm (Shimadzu, UV 1201, Japan). Each 
determination was carried out in triplicate and five tablets were analyzed 
for each formulation and the results averaged. 
 
4. Dissolution test of matrix tablets 
 
The dissolution test  was carried out using the paddle apparatus (USP 
XXIII,  method II,  Hanson Research, 72-RL, USA) at 50 rpm and 37 ºC ±  1 
ºC. Each tablet was accurately weighed and 3 tablets of each formulation 
were used. The dissolution medium consisted of 900 ml of phosphate 
buffer pH 6.8 (USP). At pre-selected time intervals,  4 ml samples were 
collected over eight hours using an automated sampler (Hanson Research, 
Dissotte 27-6A, USA). The samples removed were not replaced and the 
resultant loss in volume of the dissolution medium was compensated for 
in the calculation. The amount of drug released was determined by UV 
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 spectrophotometry (Shimadzu, UV1201, Japan) at 265 nm. At least three 
replicated runs were carried out and the results were averaged. 
 
5. Determination of polymer particle properties 
 
HPMC K15M powder particle size properties were determined using a 
laser diffraction particle sizer (Coulter,  LS230, USA). The measurement 
was based on the amount of laser light diffracted by particles. The sizer 
also provided submicron size information using the polarization intensity 
differential scattering (PIDS) method. The LS230 sizer employed laser 
light with a wavelength of 750 nm to size particles.  
 
Part II.  Study of the release performance of ethylcellulose 




Aspirin (USP grade) was used as a poorly water-soluble model drug, while 
naproxen sodium (BP grade) was chosen as the soluble model drug and 
both were used as supplied. 
 
HPMC (K4M, CR grade, Dow Chemical,  USA) was used as the matrix 
polymer. α-lactose monohydrate  (Pharmatose 200M, DMV, The 
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 Netherlands) was used as the fil ler.  In the case of aspirin, 
microcrystalline cellulose (Avicel PH 101, Asahi Chemical, Japan) was 
added as a binder to maintain reasonable tablet strength for the coating 
process. Stearic acid (Merck, Germany) was used as the lubricant in both 
cases. 
 
Ethylcellulose, in the form of an aqueous dispersion (EC, Surelease E-7-
19010,  Colorcon, USA) was used as the coating polymer. Opadry (OY-
7240 clear, Colorcon, USA) was used as a release channel agent in the 
coating formulation. Opadry is a water-soluble powder composed of 




1. Preparation of matrix tablets for coating 
 
The formulations of naproxen sodium matrix tablets are shown in Table 4. 
The batch weight of each naproxen sodium formulation was 500 g.  The 
weighed amounts of naproxen, HPMC, and lactose were first thoroughly 
mixed in the blender (Erweka, AR 401, Germany) for 30 min. The 
lubricant, stearic acid, was then added and mixed for a further 10 min.  
The  resultant  mixture was then compressed  into 625 mg  tablets,  using a 
 
47 










                       1                        2                      3                       4 

















    0.00 
 


























 single  punch tablet  machine  (Manesty, E2, UK)  with  9.5  mm  
diameter concave punches.  The quantity of naproxen sodium in each 
matrix tablet was kept constant at 250 mg, while the concentration of 
HPMC was varied.  For the evaluation of the impact of polymer content 
on drug release behaviour, polymer concentrations of 0 %, 15 %, 30 % 
and 45 % respectively were used.  
 
The formulations of the aspirin matrix tablets are given in Table 5.  The 
batch weight of each formulation was 500 g. The powder blend was 
prepared according to the procedure for naproxen sodium-HPMC matrix 
tablets.  Similarly, the resultant mixture was then compressed into 350 mg 
tablets.   The amount of aspirin in each matrix tablet was kept constant at 
120 mg, while the concentration of HPMC was varied. Polymer 
concentrations of 0 %, 10 %, 15 % and 20 % were used to evaluate the 
effects of HPMC level on drug release performance. 
 
2. Determination of drug content of matrix tablets 
 
The drug content was determined according to the procedure described 
earlier (Experimental,  Part  I,  Method B3). Aspirin was assayed 




 Table 5.  Formulations of aspirin matrix tablets for EC coating 
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 3. Preparation of coating dispersion 
 
The Surelease dispersion (as supplied) consisted of 25 % w/w solids 
content and was found unsuitable to be sprayed directly. Thus, dilution of 
Surelease dispersion was required. An amount of 66.7 g of distilled water 
was added to 100.0 g of Surelease dispersion with constant stirring for 30 
min, and this reduced the level of solids to 15 % w/w. 
  
A 15 % w/w Opadry solution was prepared separately by adding 15 g of 
Opadry in 85 g of distil led water.  The mixture was stirred for 1 h to form 
a homogeneous solution. Appropriate amount of this solution were then 
added to the diluted Surelease dispersion to obtain final mixtures 
consisting of 10 %, 20 % and 30 % of the Opadry with respect to the total 
coating solids. The Surelease :  Opadry mixtures were stirred thoroughly 
using a paddle stirrer at 200 rpm for another hour. 
 
4. EC coating process 
 
The matrix tablets were coated using a side-vented coating machine 
(O’Hara Technologies, Labcoat I,  Canada). The side-vented pan had 
perforations and a coating capacity of 0.5 to 1 kg tablets.  The coating 
parameters employed for naproxen sodium and aspirin are given in Tables 
6 and 7 respectively. 
51 
  










      0 
 
     10 
 
    20 
 
  30 
 
 
Tablet load (g) 
    
    680 
    
     700  
    
    710  
    
   690 
Inlet air temperature 
(°C) 
 
       
     70 
      
     69 
     
    68 
     





       
     47 
      
     47 
     
    47 
     
    49 




     12  
 
     12 
 
    13-15 
 





     2.1 
 
     2.1 
 
     2.1 
 
    2.1 




     2.0 
 
     2.0 
 
     2.0 
 
    2.0 
Pan pressure 
difference   (mbar) 
 
 
    -0.3 
 
    -0.3 
 
     -0.2 
 


















   





    
      0 
     
      10 
       
      20 
       
     30 
 
     
 
Tablet load (g)  
 
 
      680 
 
      700  
 
      700  
 
     700  
 
Inlet air Temp. (°C) 
 
 
      57 
 
      59 
 
    56-63 
 
   56-63 
 
Bed Temp. (°C) 
 
 
      43 
 
   39.7-43 
 
      39 
 
   40-45 
 
Pan rotation speed (rpm) 
 
 
    10-12  
 
       12 
 
      12 
 
     12 
 
Atomizing air pressure 
(bar) 
 
      1.4 
 
       1.3 
 
      1.4 
 
     1.4 
 
Pattern air pressure (bar) 
 
 
      1.4 
 
       1.4 
 
      1.4 
 
     1.4 
 




      -0.9 
 
       -0.9 
 
      -0.9 
 








 5. Determination of amount of coating applied to matrix tablets    
 
Determination of the average coating weight gain applied to each batch 
was carried out by taking 40 accurately weighed yellow placebo tablets 
marked with a number from 1 – 40, and mixing together with white active 
tablets for coating. As the coating was transparent, the yellow colour and 
marking of the placebo tablets was not masked. The purpose of these 
placebo tablets was to enable calculation of the actual coating weight gain 
from each theoretical coating condition. The active tablets consisted of 
equal number of matrix tablets of different core formulations,  
differentiated by marking on the tablets. The tablets were coated together 
in a single batch to avoid variations due to uncontrollable differences in 
coating conditions. Tablets were coated to theoretical weight gains of 2 
%, 4 %, 6 %, 8 % and 10 %. At each theoretical weight gain point, 10 of 
the marked placebo tablets were removed, accurately weighed and then 
returned back to the batch. Difference of weight before and after coating 
was divided by the original tablet weight. The percentage, representing 
actual coating percentage weight gain per tablet,  was calculated and the 
ten individual tablet results were averaged.  
 
6. Dissolution test of coated matrix tablets 
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 The dissolution test was carried out according to the procedure described 
earlier (Experimental,  Part I,  Method, B4), aspirin was assayed 


















 IV. RESULTS AND DISCUSSION 
 
Part I. Influence of HPMC particle properties on release of 
aspirin from HPMC matrix tablets 
 
1. HPMC particle properties 
 
HPMC K15M was divided into different size fractions using sieves of 
different mesh sizes. The mean particle size, median particle size, and 
volume distribution of each size fraction were determined. A total of 3 
runs for each size fraction was carried out and the results were averaged 
(Table 8). Particle size properties of unsieved HPMC K15M are also listed 
in Table 8. 
 
As shown in Table 8, the mean particle size of unsieved HPMC K15M was 
almost the same as that of the 70 - 80 µm sieve aperture size fraction, 
both around 110 µm. However, their size distribution patterns were very 
different.  Distribution span for unsieved HPMC K15M was 2.34, about 
double the value of the 70 - 80 µm sieve aperture size fraction. This 
indicates that the particle size distribution of the unsieved HPMC powder 
was much wider compared to the sieved fraction.  
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 Table 8. Particle characteristics of unsieved HPMC K15M and its different size fractions 
 
 
Sieve                 Mean particle      Median  particle Size      Number of      Volume percentage 
aperture               size                size                 distribution   particles per unit  of counted 
size          span    volume*       particles 
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20 - 30 µm           34 µm   34 µm  1.39      604118      98.58 % 
 
40 - 50 µm        58 µm  56 µm  1.37      341696      99.03 % 
 
70 - 80 µm            113 µm  113µm  1.24      126922      99.96 % 
 
100 - 120 µm        180µm  181µm  1.02      35536      99.97 % 
 
160 - 200 µm            309 µm  307µm  0.996      4488      100.00 % 
 
unsieved           112 µm  111µm  2.34      197370      99.70 % 
 
 









 The volume percentage of the HPMC particles in each size fraction was 
slightly less than 100 % because particles smaller than 1 µm were not 
included. 
 
2. Effects of HPMC particle size on release of aspirin from matrix 
tablets 
 
I t  was observed that the particle size of HPMC played an important role in 
determining the release of aspirin from the matrix tablet.  The rate of 
aspirin released from the matrix tablet was affected by the particle size of 
HPMC to different extents (Figures 1-5). The drug release rate generally 
decreased as the HPMC mean particle size decreased, 309 µm > 180 µm > 
113 µm > 58 µm = 34 µm.  A markedly higher rate of drug release was 
observed when the mean particle size of HPMC was greater than 113 µm 
and the magnitude of the effect was also dependent on the concentration 
of HPMC in the matrix tablet.  In contrast,  less significant effects of 
particle size change on release rate were observed when HPMC of mean 
particle size 113 µm or smaller was employed within the range of polymer 
concentrations studied.  Matrix tablets produced from HPMC with mean 






























Figure  1. Effect of different HPMC K15M particle size fractions on aspirin  release,  at  
HPMC  content  of  5 %. Mean  particle  size :  ({) 309 µm    (z) 180 µm   () 113 µm   






























Figure 2. Effect of  different HPMC K15M particle size fractions on aspirin release,  at 
HPMC content of  10 %. Mean particle size:  ({) 309 µm    (z) 180 µm   () 113 µm   

















0 100 200 300 400 500











Figure 3. Effect of  different HPMC K15M particle size fractions on aspirin release,  at 
HPMC content  of  20 %. Mean particle size:  ({) 309 µm    (z) 180 µm   () 113 µm   





























Figure  4. Effect of  different HPMC K15M particle size fractions on aspirin release,  at 
HPMC content of  30 %. Mean  particle  size:  ({) 309 µm   (z) 180 µm   () 113 µm   
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Figure  5. Effect of  different HPMC K15M particle size fractions on aspirin release,  at 
HPMC content  of  40 %. Mean  particle  size:  ({) 309 µm   (z) 180 µm   () 113 µm   
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Figure  6.  Effect of different concentrations of unsieved HPMC K15M on aspirin release 
from matrix tablets. HPMC concentration in the core :  ({) 0 %   (z) 10  %  () 20 % 





 content was less than 20 %.  This effect was not observed with higher 
concentrations of HPMC.   Where HPMC particle size was larger than 180 
µm, rapid drug release was seen at all  the polymer concentrations studied.  
For polymer particles smaller than 113 µm, the burst effect was only 
apparent at  the 5 % HPMC level. For all  HPMC particle size fractions, it  
was found that aspirin release rate decreased as HPMC content increased 
in the formulation (Figures 1-6).   
 
3. Effects of HPMC particle size on release kinetics of aspirin  
 
In a polymer matrix system, segments of the polymer chain are 
continually in motion, thus creating voids. When the volume of these 
voids is of the same magnitude as the volume of a liquid molecule, these 
motions enable liquid molecules to pass through the polymer chains. This 
is how the hydration of the polymer and drug diffusion process is 
governed. Therefore, release kinetics expressing the diffusion of drugs 
from HPMC matrix is closely related to these motions. There are 3 
possible situations governing drug release. 
 
In situation I,  HPMC in the matrix system is in the rubbery state and the 
chains adjust very quickly to the presence of a molecule of liquid. The 
rate of diffusion of the liquid is much less than the rate of relaxation of 
the polymer units,  giving rise to Fickian diffusion. The amount of 
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 diffusing substance released at time t  can be expressed by Higuchi release 
model.   
 
In situation II,  the polymer relaxation process is very slow or the volume 
of void is small compared with the rate of diffusion. The liquid diffuses 
through the polymer with a constant velocity showing an advancing front 
that marks the penetration limit of the liquid. Behind this advancing front, 
the polymer may transform into a swollen gel or rubbery polymer, while 
ahead of this front,  the polymer free of liquid remains in the glassy state. 
The amount of drug released at t ime t  follows zero order kinetics.  
 
In situation III,  the rates of diffusion of the liquid and relaxation of the 
polymer are of the same order of magnitude, giving rise to non-Fickian 
diffusion. This situation lies between situation I and situation II and the 
amount of drug released at t ime t  follows first  order release pattern. 
 
In the current research work, HPMC mean particle size of 113 µm was 
identified as the threshold size for changes in drug release kinetics. Table 
9 shows that the drug release mechanism was affected by HPMC mean 
particle size and HPMC concentration. When the HPMC mean particle 
size was 113 µm or smaller, the dissolution profiles generally gave a 
better  fi t   with  first   order  kinetics,   which  was  observed  for  all   the 
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 Table 9.   Kinetic parameters of aspirin release from matrix tablets formulated with different HPMC size 
fractions  
 
                                         Korsmeyer-Peppas Equation Zero Order Equation        First   Order Equation   Higuchi   Equation 
                      
Content  Mean HPMC             n  R2          K0          R2              K1      R2        KH          R2 
of  HPMC particle size     (% min-1 )                      (min -1 )                                   (% min -1/2 ) 
 
    5%  309 µm                    0.2950 0.9509        *            0.0250     0.9822       * 
180 µm                    0.3070 0.9833        *            0.0269     0.9728       * 
113 µm                 0.3290 0.9844        *            0.0208     0.9715       * 
58   µm                       1.0130 0.9911         *            0.0170     0.9541       * 
34   µm                       0.8650 0.9853       *            0.0173     0.9887       * 
 
10%  309 µm                   0.2046  0.9919      *            0.0278             0.9162       * 
180 µm                0.2582    0.9506      *         *         * 
113 µm                  0.6085 0.9996  0.1947         0.8753          0.0034      0.9923     3.5378         0.9889           
58   µm             0.7053 0.9973  0.1602         0.9258          0.0024      0.9921     2.8764         0.9720 
34   µm                       0.8114 0.9881  0.1596         0.9319          0.0024      0.9931     2.8593         0.9652 
 
20%  309 µm           0.2809  0.9923      *            0.0073      0.9366        * 
180 µm                  0.5170   0.9911      *            0.0037      0.9450         3.8706         0.9923 
113 µm                       0.6707 0.9993  0.1382         0.9185          0.0019      0.9834     2.4895         0.9746 
58   µm            0.8136 0.9954  0.1278         0.9602          0.0017      0.9942     2.2464         0.9445 
34   µm              0.8445 0.9967  0.1222         0.9808          0.0016      0.9991     2.1254         0.9241 
 
30%  309 µm           0.3938   0.9919       *            0.0062      0.9348     4.9491         0.9264 
180 µm              0.5091 0.9962  0.1650       0.8436          0.0025      0.9604     3.0380         0.9942 
113 µm                 0.6011 0.9970  0.1223         0.9014          0.0016      0.9668     2.2098         0.9821 
58   µm                       0.7525 0.9985  0.1043         0.9548          0.0013      0.9868     1.8550         0.9547 
34   µm                       0.8054 0.9977  0.1071         0.9668          0.0013      0.9905     1.8969         0.9492 
 
40%  309 µm                  0.3763 0.9935         *            0.0054      0.9477     4.6500         0.8962 
180 µm             0.5933 0.9990  0.1157         0.9005          0.0015      0.9634     2.0914         0.9841 
113 µm                       0.8031 0.9977  0.0951         0.9682          0.0012      0.9917     1.6831         0.9447  67 58   µm            0.8285 0.9947  0.0974         0.9686          0.0012      0.9923     1.7235         0.9435 
34   µm                       0.7627 0.9983  0.0947         0.9610          0.0011      0.9878     1.6822         0.9509  
 
 
*:  R2  too low, not applicable 
 
  
HPMC concentrations studied. However, for HPMC mean particle size of 
180 µm at HPMC concentration 20 % and above, the drug release 
mechanism gave best fit  with the Higuchi kinetic model. At lower HPMC 
concentrations, the drug release mechanism was best described by the first 
order kinetics. The release mechanism for HPMC mean particle size of 
309 µm at concentrations of 10 % and above did not fit  with any of the 
models. This indicated that the magnitude of HPMC chain motion and 
volume of voids created were closely related to size of HPMC particles.  
 
The effect of variation in polymer particle size distribution on drug 
release was also investigated by using sieved and unsieved HPMC powder 
of similar mean particle size. The unsieved HPMC powder had a mean 
particle size of 112 µm. Hence the 70 – 80 µm sieve aperture size fraction, 
which had a mean particle size of 113 µm was used in this study. Size 
distribution span of the unsieved HPMC powder was 2.34. In contrast, the 
size distribution of the 70 – 80 µm sieve aperture size fraction was 
narrower, with a distribution span of 1.24.  Release profile and kinetic 
parameters for matrices prepared from the unsieved HPMC powders are 
shown in Figure 6 and Table 10.  Changes in polymer size distribution 
generally did not affect the release mechanism within the HPMC 
concentration range studied.  Drug release for both the sieved and 
unsieved polymer powders gave best fit  with the first  order release model.   
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 However, as indicated by the release constant of the first  order kinetics, 
K1 ,  differences in release rates were observed when the HPMC 
concentration was lower than 20 % (Tables 9 and 10).  When the HPMC 
concentration was above 20 %, differences in release rate were not 
apparent.  
 
The influence of polymer particle size could be explained by the binding 
efficiency of HPMC particles during gel layer formation. There are 
several basic factors governing the effective formation of HPMC extended 
release gel layer. Firstly, the polymer must hydrate sufficiently fast when 
wetted by the dissolution medium.  Next, the hydrated polymer should 
swell and form a viscous gel.  Finally, there must be sufficient adjoining 
HPMC particles present to provide contact and entanglement of the 
polymer chains, to produce a continuous and strong diffusion barrier on 
the surface of the matrix tablet.  If the swelling polymer particles could 
not be in contact or bind with adjacent polymer particles, a strong and 
continuous release barrier would not be able to form. In addition, the 
matrix tablet would break-up readily as the pressure is generated within 
the tablet by swelling of the polymer particles with water uptake.  Thus, 
drug would be released rapidly and the matrix tablet would be deemed as 




Table 10. Kinetic parameters of aspirin release from the matrix tablets formulated with unsieved HPMC and 
different fil ler types 
 
 
Korsmeyer-Peppas   Zero Order   First Order  Higuchi Equation  
Equation     Equation     Equation               
 
Filler      HPMC  n    K               R2            K0              R2                 K1    R2                     KH            R2 
type      content              (% min-1 )                    (min -1 )                                 (% min -1/2 ) 
 
Lactose      0%              1.1052      1.074   0.9917  1.0850  0.8220         0.0315        0.9757        9.393    0.9091 
     10%             0.7136       0.919 0.9981  0.1687   0.9436         0.0027        0.9869            3.046              0.9671 
     20%             0.7394       0.594 0.9947  0.1265    0.9468          0.0017        0.9901          2.282      0.9619 
     30%              0.8445       0.292 0.9958  0.1136  0.9680            0.0016        0.9983     2.033      0.9442 
     40%              0.8302       0.277 0.9937  0.1011  0.9765            0.0013        0.9963     1.804      0.9370  
     50%              0.8096       0.286 0.9725  0.0898    0.9621            0.0011        0.9875     1.613      0.9532 
 
DCP         0%                0.3953        9.645     0.9730           *                                           *                              * 
     10%              0.4546       4.531 0.9943           *                                           0.0029   0.8821      3.455     0.9835      
     20%              0.6296          1.177     0.9926  0.1309    0.8629           0.0017        0.9496     2.238      0.9905 
     30%             0.7377       0.506 0.9939  0.1040  0.9265           0.0013        0.9711     1.867       0.9711 
     40%              0.7499               0.395 0.9897  0.0910  0.9603           0.0010        0.9809     1.618      0.9515 
     50%              0.8005       0.289      0.9966  0.0884  0.9752           0.0011        0.9939     1.561      0.9385 




 depends on the matrix water uptake ability, extent of swelling, distance 
between adjacent polymer particles, as well as the strength of the 
diffusion gel layer formed.   
 
The results obtained in this study suggested two possible phenomena to 
explain the bahaviour as polymer particle size was decreased. Firstly, for 
the same amount of polymer, reduction of particle size numerically 
increased the number of particles and hence the number of contact points 
available for binding of the swelling particle also increased. This would 
favour the formation of a continuous gel layer that would retard drug 
release, as well as inhibit  further penetration of water into the tablet core.  
Secondly, a smaller polymer particle would produce a lower pressure 
differential  on swelling when compared to a larger particle. Thus, the 
smaller polymer particles were less likely to cause disintegration of the 
matrix tablets. The above two effects aptly explained the lower release 
rate with decreasing HPMC particle size.  Increasing HPMC content or 
reducing particle size could, to some degree, achieve similar drug release 
rate retarding effect. Depending on the concentration of HPMC in the 
tablet core, the release retarding effects due to particle size reduction 
leveled-off at a specific polymer particle size value. Further size 
reduction did not provide any significant change to the dissolution 
profile. At low HPMC concentrations, there are likely to be areas at the 
surface of the matrix tablet where there is no HPMC (Mitchell et al,  
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 1993a). In their study, the smaller particles had approximately 3 times the 
surface area of the larger ones and spread more extensively over the entire 
matrix and reduced the size of the HPMC-free area.  
 
From the current research, HPMC content was identified to be very 
important because of its influence on the effects of HPMC particle size 
and size distribution. It  was observed that maintaining HPMC content 
above 20 % was helpful in developing a robust extended release matrix 
system. The matrix system prepared with 5 % HPMC released 80 % of the 
drug within 2 h and showed unpredictable release behaviour. Varying 
HPMC concentrations at levels below 20 % caused significant changes in 
the release rates, irrespective of the polymer mean particle size.   
Similarly, differing polymer size distribution exerted significant influence 
on drug release rate when the polymer level was less than 20 %. Hence, 
matrix systems with less than 20 % HPMC showed greater polymer 
particle size and size distribution sensitivity. When the polymer content 
was above 20 %, the influence of HPMC particle size and size distribution 
was significantly reduced. 
 
With water insoluble drugs, hydrophilic matrix formulation might involve 
low HPMC concentrations. Therefore, i t  is essential that consideration be 
given to the influence of particle size and size distribution of the 
component polymer material,  when developing matrix systems. 
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4. Quantitative relationship between drug release rate and HPMC 
particle properties 
 
Several basic factors govern the formation and the extended release 
performance of a gel layer. Previous investigations proposed that the 
formation of the continuous gel layer was controlled by polymer hydration 
speed, polymer chain relaxation and swelling and availability of sufficient 
adjoining HPMC particles to provide contact and entanglement of polymer 
chains, thus producing a continuous barrier. It  was also reported that 
increasing compression force could significantly affect tablet hardness 
and thickness, which would subsequently alter tablet porosity, tortuosity 
and surface area. However, minimal effects of compression force on drug 
release from HPMC tablets were observed (Baveja et al. ,  1988). This 
indicated that the initial  surface area, porosity and tortuosity of the 
tablets had changed markedly during the process of polymer swelling and 
formation of the extended release gel layer or that drug release was 
independent of these tablet physical properties.  Drug release performance 
is however expected to be more closely related to porosity and tortuosity 
of the gel barrier used to control the rate of drug diffusion, as well as the 
strength and viscosity of the gel layer to resist rapid erosion rather than 
the porosity of the original tablet matrix. 
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 In this study, it  appeared that polymer content,  particle size, particle 
distribution and number of particles could directly influence the 
availability of adjoining particle contact points, viscosity, porosity and 
tortuosity of the gel layer. Increase in the size of particles of a constant 
total number or increase in the number of particles of equal size can both 
lead to higher degree of chain entanglement. This will  result in a less 
porous and more tortuous diffusion barrier for drug release and water 
penetration into the tablet core. 
 
With a higher polymer concentration per unit  area, the resultant gel layer 
would be more viscous and consequently more resistant to erosion. For 
the layer containing polymer particles of similar size, the higher the total 
number of particles, the slower the drug release will be. For the same 
number of particles, the larger the polymer particles are, the slower the 
release will  be.  
 
For similar polymer content,  reduction of particle size is accompanied by 
numerical increase in the polymer particle quantity. However, the effects 
of numerical increase in particle number were counteracted by the effects 
of particle size reduction. 
 
According to the drug release models of the matrix tablets studied 
(Results and Discussions. Part I .3), the matrix tablet showed three 
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 different release characteristics as particle size decreased: matrix 
disintegration at large particle size level,  release by diffusion at medium 
size level and a combination of both erosion and release by diffusion at 
fine size level.  
 
Within the polymer concentration range studied, large particles upon 
swelling could not effectively bind with adjacent ones due to insufficient 
availability of polymer particles at immediately adjacent locations. Thus, 
the isolated polymer particle functioned as a disintegrant rather than a 
release-retarding agent. Pressure from the individual isolated swelling 
polymer particles was relieved by the matrix disintegration process. The 
medium-sized particles occurred in larger numbers and were able to be 
formulated with statistical possibility of the presence of adjacent polymer 
particles for binding to form a continuous gel structure that controlled 
drug release by diffusion. Erosion of the hydrophilic gel structure had a 
considerably lower influence on drug release compared to the diffusion 
process. This was indicated by the better fit  of the drug release kinetics to 
the Higuchi square root equation. Comparatively, the fine polymer 
particles formed a less porous and more tortuous gel structure. Therefore,  
release mechanism depended on a combination of both diffusion and 
erosion and followed first  order kinetics. Thus, the n  value of the 
Korsmeyer-Peppas equation was observed to increase with decrease in 
HPMC particle size (Table 9).  
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Diffusion rate is known to be directly proportional to pore size and pore 
number. According to Fick’s law, diffusion rate decreases as the mean 
length of the diffusion route increases. Quantitative relationships between 
drug release and porosity or tortuosity of extended release barriers have 
been previously proposed (Robert and Donald, 1984). Drug release from 
porous matrices, which follow the Higuchi model, can be described by the 
following equation: 
 
Mt = (Dε(2A – εCs) Cs t/τ)1 /2                          (13) 
 
where  Mt  is the amount of drug released at time t ,  D  is the diffusion 
coefficient of drug in the solvent penetrating the matrix, A  is the total 
amount of drug in the matrix sytem,  Cs  is the solubility of the drug in the 
solvent penetrating matrix substance, ε  is the porosity and τ is the 
tortuosity of the matrix gel layer which is a measure of diffusional 
distance in excess of the linear path that the solute would travel. It  has 
been suggested that the gel layer might show different viscosity values 
under different conditions (Leszek, 1987). According to Einstein and 
Stoke's equation, diffusion coefficient decreases proportionately as the 
viscosity increases (Leszek, 1987): 
 
D = R.T / (6π .  N. γ .  η  )                                    (14) 
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 where D  is the diffusion coefficient, R  is the gas constant, T  is the 
temperature, N  is the Loschmidt’s number,  γ  is the particle radius and η  
is the viscosity. 
 
From the above findings in  literature, factors affecting viscosity, porosity 
and tortuosity of the gel structure were found to have quantitative 
relationships with drug release rate. In the present study, it  was also 
found that the drug release rate was affected by the polymer particle 
numerical quantity and particle size.  
 
Consequently, a quantitative assessment of the effects of these two factors 
on drug release was carried out. As polymer particles were distributed in 
three dimensional space of the matrix, a cube root relationship between 
drug release constant and polymer particle quantity was expected. For 
each formulation, three dissolution runs were carried out and the mean 
value of the first order release constant K1  obtained. The release constants 
were plotted against the corresponding cube root of the relative number of 
polymer particles for different concentrations of the polymer employed 
(Figure 7).  A good linear relationship was demonstrated within each size 
fraction. The  R2   values  for  the  size  fractions  with  mean  particle  
size of  34, 58, 113, 180 and 309 µm  and  for  the  unsieved  material 
(112 µm) were 0.9962, 0.9927, 0.9786, 0.9941, 0.9985 and 0.9708, 
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Figure  7.  First order release constant K1 versus number of HPMC particles. HPMC 
mean  particle  size:  () 309 µm   () 180 µm   () 113 µm   (◊)  58 µm   (z) 34 µm  
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Figure  8.  First  order  release  constant  K1  versus   number  of    HPMC   particles   and  
mean particle size. HPMC mean particle size : () 309 µm  () 180 µm  () 113 µm    
(◊) 58 µm  (z) 34 µm  ({)  unsieved (112 µm) 
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 l inearity with R2  value of 0.9394. This indicated that the effects of  
polymer  particle  size  on  K1   value  were significant and should not be 
neglected. The summative effect of polymer particle size and relative 
particle number on the drug release constant is depicted in Figure 8. A 
good linear relationship (R2  of 0.9698) represented by Equation 15  was 
demonstrated. 
 
K 1 =  d/ (Np o l y m e r   X Pp o l y m e r)1 / 3  + a     (15) 
 
where Np ol y m e r  refers to the relative number of polymer particles in the 
formula, Pp ol y m er  is the mean particle size of the polymer powder and d  is 
a constant indicating sensitivity of the matrix system to changes in 
particle size and polymer quantity. The value, a ,  is a release retarding 
constant. The values for d  and a  were found to be 0.3969 and –0.0020 
respectively. The above relationship is applicable to matrix systems 
capable of forming an effective gel layer without disintegration and with 
release mechanism composed of erosion and diffusion. 
 
The application of the equation was further verified by the use of a 
different matrix system consisting of insoluble dibasic calcium phosphate 
as filler instead of soluble lactose. The concentration of unsieved HPMC 
powder used was varied from 10-50 %. The mean value of K1 ,  obtained 
from three determinations was plotted against the corresponding 1/(N 
79 
 p o l y m e r X Pp ol y m er)1 / 3 .  A good linear relationship between the two factors 
was demonstrated (R2  0.9781, Figure 9). d  and a  values were found to be 
0.4035 and –0.0018 respectively and were very close to the values 
obtained from the matrix system with lactose as the filler.  This suggested 
that the type of fi llers had li ttle impact on drug release rate. Hence, no 
significant difference in the drug release rates between soluble fil ler and 
insoluble fillers was found. This finding agrees with earlier findings of 
other researchers (Gao et al. ,  1996 and Rekhi et al. ,  1999). 
 
The findings of the current study have important practical applications. 
Firstly, it  demonstrates that it  is possible to achieve consistent batch-to-
batch extended release performance for HPMC matrix systems of varied 
polymer particle size properties. One simple approach is to use polymer 
powder with particle size below that of the critical threshold. If the 
threshold size is very small and it  becomes impractical and expensive to 
implement, the equation could be employed to achieve the same goal. By 
examining the polymer mean particle size and particle number per unit 
volume of each batch, the equation could be used to predict the actual 
polymer content needed for that particular batch to give the same K1  value 
from the first batch. By this approach, the undesirable influence from 
variations of polymer particle size could be minimised. Secondly, the 
equation can help to predict drug release performance of systems with 
80 
 varying polymer content and particle size and hence reduce the number of 
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Figure  9.  Effect of HPMC particle properties on first order release constant K1 using 











 Part II.  Reservoir dispersed matrix tablets 
 
1. EC coating level on matrix tablets 
 
In this part of the study, the effect of EC coating level on drug release 
from matrix tablets was investigated. HPMC of a lower viscosity grade (K 
4M) was employed to better observe the effect of the EC coating. For each 
batch, the active tablets were mixed together with 40 marked and pre-
weighed placebo tablets of  the same size  and shape. As the Surelease 
(EC) coat is a clear membrane, the yellow placebo tablets were 
distinguishable from the active tablets.  At each theoretical Surelease 
coating weight gain point, samples were removed for dissolution studies. 
Ten placebo tablets were also withdrawn, weighed and then returned back 
to the coating batch. The average weight increase of the placebo tablets 
against their original weights was considered as the actual weight of 
coating (expressed as a percentage) applied to the tablet batch at that 
point.  The results are shown in Table 11. 
 
2. Effects of HPMC content 
 




 Figures 10 and 11 show that HPMC content had an effect on the release 
rates of both water-soluble naproxen sodium and less water-soluble 
aspirin. A higher HPMC content resulted in a slower release rate,  which is 
in agreement with the findings presented in Part I .  As more HPMC 
particles were available in the matrix with the increase of HPMC content, 
a faster and stronger polymer gel layer formation was expected. 
 
For  a  poorly  water  soluble  drug,  in  the  HPMC  concentration  range  
studied, the following results were observed. Without HPMC in the tablet 
core, release of aspirin from the matrix tablet was completed within 2 h.  
However, increase of HPMC content to 20 % decreased aspirin release to 
less than 50 % within 8 h. The impact of HPMC content on the aspirin 
release rate was significant.  10 % HPMC in the matrix formulation was 
sufficient to give rise to 8 h controlled release.  
 
For a water soluble drug like naproxen sodium, higher HPMC levels were 
needed to achieve the corresponding controlled release effect than for a 
poorly water soluble drug. The HPMC concentrations studied varied from 
zero to 45 %. Without HPMC in the core, more than 95 % of naproxen 
sodium was released within 30 min, much faster than that from the 
corresponding aspirin tablet.  With HPMC level at 15 %, about 90 % of the 
drug was released into the dissolution media in 6 h.  When the HPMC 
content  was   increased  to  30 %,  a  marked  drop  in  release  rate   was  
83 
 Table 11. Amounts of coating applied to matrix tablets using dispersions 
of Surelease with varying amounts of Opadry 
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*  Coating level too low to show release difference for naproxen sodium 
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Figure  10.  Effect of  different HPMC levels on naproxen sodium release from uncoated 














0 100 200 300 400 500












Figure  11.  Effect of  different HPMC levels on aspirin release from uncoated matrix 
tablet.   () 0 % HPMC     () 10 % HPMC    (z) 15 % HPMC    ({) 20 % HPMC 
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 obtained, with only 65 % of drug released in 6 h.  At 45 % of HPMC 
content, less than 50 % of drug was released within 8 h. Clearly, the 
water-soluble drug was sensitive to the HPMC content in the matrix. 
 
2.2 Effects of HPMC content on drug release kinetics from uncoated 
tablets 
 
The kinetic models of aspirin and naproxen sodium release profiles are 
shown in Tables 12 and 13. 
 
When HPMC was not included in the formula, the release of aspirin 
followed zero order with R2  of 0.9859. As HPMC content in the matrix 
increased to 10 %, 15 % or 20 %, release kinetics changed to Higuchi 
model,  with R2  of 0.9922, 0.9834 and 0.9799 respectively. Varying n 
value from the Korsmeyer - Peppas equation indicated a trend of release 
kinetic change with a increasing HPMC content.  
 
Without HPMC, the release of naproxen sodium followed a first order 
model with R2  of 0.9936. As HPMC content in the matrix increased to 15 
%, release kinetics still  fitted to first order model, with R2  of 0.9887. 
When HPMC concentration was further increased to 30 % and 45 %, 
release pattern changed to Higuchi model, with R2  of 0.9835 and 0.9896 
respectively. However, n value obtained was constant at 0.6. 
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EC coating       Opadry          HPMC         Zero order equation  First order equation       Higuchi  equation        Korsmayer- Peppas equation 
Level  (%)        concentration      content in          K0   R2                           K1          R2            KH           R2                   n   R2
            in EC coat ( % )     core tablet ( % )     ( % min-1 )   ( min-1 )   ( % min -1/2  ) 
 
 
0      0    0      0.8814            0.9859           0.0173      0.8911           7.6304        0.8854            0.8320          0.9940 
0      0   10      0.2089     0.7091           0.0040        0.9795            3.8161        0.9922            0.6035         0.9975 
0      0   15      0.1449            0.7822           0.0020      0.9763            2.6268        0.9834            0.6499      0.9962 
0      0   20      0.1191 0.8288           0.0015      0.9672           2.1511        0.9799            0.6957          0.9952 
 
1.78      0    0       0.6870 0.9835           0.0097         0.9814            13.2110        0.9944            1.9618           0.9760 
1.78      0   10      0.0618            0.9977           0.0007         0.9975            1.7155        0.9771            1.0579           0.9971 
1.78      0   15      0.0552            0.9973           0.0006         0.9961            1.4759        0.9695            0.9100           0.9822 
1.78      0   20                            0.0408           0.9892           0.0004         0.9939            1.0792        0.9911            0.9879           0.9923 
 
3.36      0    0                   0.0201            0.9958           0.0002         0.9968             0.6330        0.9946            1.4512            0.9403    
3.36      0   10      0.0118            0.9915          0.0001         0.9905             0.3885        0.9558           1.4994            0.9712 
3.36      0   15      0.0132            0.9691          0.0001         0.9497             0.5033        0.9581            1.2653            0.9561 
3.36      0   20      0.0109            0.9874         0.0001         0.9878             0.4092        0.9902            1.2414           0.9870 
 
4.06     10   0      0.0153           0.9803          0.0002         0.9703             0.5135        0.9849             0.8686           0.9784    
4.06     10                  10               0.0141           0.9920          0.0001         0.9926            0.3179        0.9420            0.9909           0.9742 
4.06     10                  15                             0.0095           0.9640          0.0001         0.8635             0.3080        0.9288           1.7266            0.9677 
4.06                        10                  20                             0.0256           0.9964          0.0003         0.9956             1.0003        0.9911           4.3370            0.9901 
 
6.28      10    0      0.0134            0.9775           0.0001         0.9794            0.4034        0.9893            0.8452          0.9940 
6.28      10   10      0.0082     0.9860           0.0001         0.9889            0.2407        0.9960            0.9559          0.9886 
6.28      10   15      0.0079            0.9855           0.0001       0.9858            0.2183        0.9795            1.0419      0.9890 
6.28      10   20      0.0008 0.9819           0.0001       0.9715            0.2230        0.9746            1.1330          0.9777 87  
 
 




EC coating       Opadry          HPMC         Zero order equation  First order equation       Higuchi  equation        Korsmayer- Peppas equation 
Level  (%)        concentration      content in          K0   R2                           K1          R2            KH           R2                   n   R2
            in EC coat ( % )     core tablet ( % )     ( % min-1 )   ( min-1 )   ( % min -1/2  ) 
 
 
1.60      20    0      1.4602            0.8981           0.0524         0.9945        13.6070        0.9088          2.1434          0.9651         
1.60      20                 10      0.1996            0.9793           0.0032         0.9941          4.7431          0.9987          0.8922          0.9881 
1.60      20                 15                           0.1264            0.9749           0.0017         0.9983          3.0621          0.9948          0.7978          0.9994   
1.60      20                 20       0.1193             0.9772          0.0016         0.9978          2.9112          0.9942          0.8081          0.9993 
 
3.79      20    0      0.6151            0.9785           0.0131         0.9933        10.2050        0.9672          1.9283          0.9048 
3.79      20   10      0.2067     0.9871           0.0040         0.9892          4.6607          0.9752          1.2164         0.9572 
3.79      20   15      0.0922            0.9996           0.0011       0.9900          2.5155          0.9774          1.0128    0.9988 
3.79      20   20      0.0794 0.9982           0.0009       0.9942          2.1181          0.9752          0.9431          0.9988 
 
6.09      20    0      0.0758            0.9873           0.0007         0.9571          1.5150          0.8728          2.1623          0.9965 
6.09      20   10      0.0678     0.9566           0.0007         0.9156          1.9445          0.9316          1.3489          0.9576 
6.09      20   15      0.0653            0.9798           0.0007       0.9698          2.2842          0.9555          2.2193    0.9792 
6.09      20   20      0.0635 0.9944           0.0007       0.9890          2.2327          0.9790          2.1746          0.9960 
 
7.92      20    0      0.0532           0.9813           0.0006         0.9772          0.9693          0.8876          1.2683          0.9878 
7.92      20   10      0.0558     0.9581           0.0006         0.9554          1.2473          0.8267          2.6939          0.9409 
7.92      20   15      0.0434            0.9594           0.0005       0.9518          1.5114          0.9280           2.4996  0.9975 
7.92      20   20      0.0458 0.9873           0.0005       0.9841          1.7012          0.8381           1.3518          0.9598 
 
10.28      20    0      0.0204            0.9896           0.0002         0.9858          0.5775          0.9642           0.9811          0.9910 
10.28      20   10      0.0080     0.9785           0.0001         0.9664          0.1940          0.9561           1.0171          0.9548 
10.28      20   15      0.0088            0.9893           0.0001       0.9789          0.2250          0.9251           1.1264    0.9845 
.9640 10.28      20   20      0.0191 0.9769           0.0002       0.9754          0.7463          0.9652           2.0869          088 
 
 Table 12 (Continue).  Kinetic parameters of aspirin release from EC-coated HPMC matrix tablets  
 
 
EC coating       Opadry          HPMC         Zero order equation  First order equation       Higuchi  equation        Korsmayer- Peppas equation 
Level  (%)        concentration      content in          K0   R2                           K1          R2            KH           R2                   n   R2
            in EC coat ( % )     core tablet ( % )     ( % min-1 )   ( min-1 )   ( % min -1/2  ) 
 
 
1.78      30    0      2.0600            0.9561           0.0691          0.9823        20.8080             0.8522         1.6370          0.9460 
1.78      30   10      0.2141     0.9740           0.0039          0.9860          3.6373             0.9207         0.8381         0.9920 
1.78      30   15      0.1423            0.9377           0.0020        0.9889          2.5591             0.9503         0.7451    0.9973 
1.78      30   20      0.1301 0.9581           0.0018        0.9938          2.3290             0.9348         0.8516          0.9897 
 
3.71      30    0      1.3467            0.9445           0.0589          0.9555        12.8660              0.7673         1.3315          0.9210 
3.71      30   10      0.1963     0.9668           0.0035          0.9915          3.4966              0.9113         0.8644         0.9847 
3.71      30   15      0.1317            0.9487           0.0017        0.9998          3.0403              0.9959         0.6701    0.9967 
3.71      30   20      0.1191 0.9602           0.0016        0.9916          2.7785              0.9963         0.7069          0.9986 
 
5.78      30    0      1.2864            0.9733           0.0421          0.9809        15.6290              0.8709         3.8888          0.9806 
5.78      30   10      0.1412     0.9971           0.0022          0.9895          3.8749              0.9895         1.2210          0.9822 
5.78      30   15      0.0896            0.9983           0.0011        0.9901          2.4955              0.9822         1.1089          0.9964 
5.78      30   20      0.0833 0.9976           0.0010        0.9992          2.2463              0.9868         1.0154          0.9959 
 
 
7.86      30    0      0.4976            0.9368           0.0150          0.9705          9.5851               0.9586         2.4498          0.9187 
7.86      30   10      0.1579     0.9810           0.0026          0.9980          4.4159               0.9939         1.4905          0.9547 
7.86      30   15      0.0896         0.9944           0.0012        0.9936          2.5408               0.9720         1.5603    0.9632 
7.86      30   20      0.0915 0.9930           0.0012        0.9792          2.5697               0.9558         1.3367          0.9902 
 
9.11      30    0      0.3607          0.9521           0.0096          0.9866          8.4267                0.9853         2.3470          0.9448 
9.11      30   10      0.1901     0.9888          0.0037          0.9855          5.2710                0.9920         1.6690          0.9534 
9.11      30   15      0.0725            0.9927           0.0009        0.9828          2.0145               0.9474         1.1285    0.9934 
9.11      30   20      0.0665 0.9961           0.0008        0.9906          1.8398               0.9584         1.1714          0.9875 89  
 
 
 Table  13. Kinetic parameters  of naproxen sodium release from EC-coated HPMC matrix tablets 
 
 
EC coating       Opadry          HPMC         Zero order equation  First order equation       Higuchi  equation        Korsmayer- Peppas equation 
Level  (%)        concentration      content in          K0   R2                           K1          R2            KH           R2                    n  R2
            in EC coat ( % )     core tablet ( % )     ( % min-1 )   ( min-1 )   ( % min -1/2  ) 
          
 
 
0  0  0            5.7329        0.9216      0.1034       0.9939           18.493           0.9149               0.6          0.9268  
0  0  15            0.2928          0.8561            0.0051          0.9887           4.4522           0.9751             0.6          0.9985 
0  0  30                   0.2178          0.7270            0.0032          0.9629           3.3639           0.9835             0.6           0.9993 
0  0  45                   0.1244          0.6870            0.0015          0.8516           1.9261           0.9896             0.6           0.9998 
  
2.87  0  0            2.7155        0.9579      0.1055           0.9555          28.8670          0.9749            2.5           0.9774  
2.87  0  15                   0.1668          0.9996            0.0031           0.9624           4.3503           0.9652            1.1           0.9915 
2.87  0  30                   0.1261          0.9939            0.0018           0.9982           3.1504           0.9791            1.1           0.9894 
2.87  0  45                   0.0951          0.9925            0.0012           0.9990           2.5203           0.9920            1.0           0.9974 
 
4.50  0  0            2.1603          0.9848            0.0557            0.9543         24.9240          0.9714            3.5           0.9646 
4.50  0  15                   0.1561          0.9960             0.0027            0.9777          2.4052           0.7412            1.4           0.9816  
4.50  0  30                   0.1232          0.9856            0.0019            0.9693          1.9524           0.7414            1.5           0.9909        
4.50  0  45                   0.0888          0.9958            0.0011            0.9850          1.3436           0.7279            1.5           0.9941 
 
6.82  0  0            1.5570          0.9185            0.0471            0.9817         23.8710          0.9477            5.6           0.9922 
6.82  0  15                   0.1376          0.9982            0.0021            0.9863          4.1650           0.9813            1.9           0.9810  
6.82  0  30                   0.1110          0.9980            0.0015            0.9925          3.1680           0.9743            1.8           0.9803        
6.82  0  45                   0.0682          0.9973            0.0008            0.9929          1.8965           0.9670            1.4           0.9961 
 
8.83  0  0            1.5683          0.9779            0.0420            0.9453         23.6170          0.9733            4.5           0.9586 
8.83  0  15                   0.1290          0.9954            0.0018            0.9740          3.5480           0.9475            1.9           0.9903  
8.83  0  30                   0.1009          0.9978            0.0013            0.9900          2.8699           0.9670            1.7           0.9927        




 Table  13 (Continue) . Kinetic parameters  of naproxen sodium release from EC-coated HPMC matrix tablets 
 
 
EC coating       Opadry          HPMC         Zero order equation  First order equation          Higuchi  equation        Korsmayer- Peppas equation 
Level  (%)        concentration      content in          K0   R2                           K1          R2               KH           R2                    n             R2
            in EC coat ( % )     core tablet ( % )     ( % min-1 )   ( min-1 )       ( % min -1/2  ) 
          
           
 
2.65  10  0            2.7435          0.9866            0.0761            0.9441         27.1440        0.9840            2.8                 0.9854 
2.65  10  15                   0.1762          0.9895            0.0023            0.9988          3.6433          0.9900           1.1                 0.9936  
2.65  10  30                   0.1405          0.9834            0.0020            0.9979          3.2061          0.9841           1.0                 0.9942        
2.65  10  45                   0.1079          0.9893            0.0014            0.9991          2.7778          0.9920           1.0                 0.9968 
 
5.45  10  0            2.3342          0.9660            0.1044            0.8642         27.0830         0.9638           1.9                 0.9229 
5.45  10  15                   0.1525          0.9946            0.0022            0.9927          3.3920          0.9726           1.1                 0.9910  
5.45  10  30                   0.1135          0.9983            0.0015            0.9942          2.8170          0.9590           1.3                 0.9874        
5.45  10  45                   0.0869          0.9986            0.0011            0.9971          2.4011          0.9803           1.3                 0.9943 
 
7.45  10  0            2.5307          0.9680            0.0752            0.9849         33.1730         0.9360           3.3                 0.9248 
7.45  10  15                   0.1464          0.9970            0.0023            0.9758          3.6721          0.9345           1.7                 0.9845  
7.45  10  30                   0.1033          0.9974            0.0013            0.9888          2.5106          0.9388           1.6                 0.9839        
7.45  10  45                   0.0752          0.9990            0.0009            0.9943          2.0553          0.9719           1.4                 0.9961 
 
9.26  10  0            2.6452          0.9916            0.0650            0.9186         29.0090         0.9417           5.3                 0.9473 
9.26  10  15                   0.1407          0.9926            0.0020            0.9544          3.4950          0.9179           1.6                 0.9938  
9.26  10  30                   0.1088          0.9924            0.0014            0.9761          2.6517          0.9186           1.6                 0.9909        
9.26  10  45                   0.0756          0.9916            0.0009            0.9857          2.1099          0.9475           1.6                 0.9882 
 
2.91  20  0            1.7595          0.9929            0.0637            0.9284         17.5780         0.9695           1.4                 0.9960 
2.91  20  15                   0.2019          0.9552            0.0029            0.9986          3.8823          0.9931           0.9                 0.9875  
2.91  20  30                   0.1568          0.9504            0.0023            0.9980          3.4307          0.9953           0.8                 0.9924        




 Table  13 (Continue) . Kinetic parameters  of naproxen sodium release from EC-coated HPMC matrix tablets 
 
 
EC coating       Opadry          HPMC         Zero order equation  First order equation          Higuchi  equation        Korsmayer- Peppas equation 
Level  (%)        concentration      content in          K0   R2                           K1          R2               KH           R2                    n             R2
            in EC coat ( % )     core tablet ( % )     ( % min-1 )   ( min-1 )       ( % min -1/2  ) 
                     
 
 
5.44  20  0            2.3848          0.9718            0.0479            0.9933        21.2670          0.9693           2.1                 0.8868 
5.44  20  15                   0.1835          0.9832            0.0026            0.9993          4.3746          0.9889           1.2                 0.9795  
5.44  20  30                   0.1499          0.9803            0.0022            0.9995          3.5636          0.9897           1.1                 0.9874        
5.44  20  45                   0.1146          0.9844            0.0015            0.9997          2.5036          0.9668           1.1                 0.9919 
 
6.58  20  0            2.6708          0.9839            0.0670            0.9693        31.0310          0.9983           3.8                 0.9561 
6.58  20  15                   0.1726          0.9986            0.0025            0.9941          4.4863          0.9702           1.2                 0.9905  
6.58  20  30                   0.1357          0.9986            0.0020            0.9861          3.3829          0.9681           1.2                 0.9853        
6.58  20  45                   0.0990          0.9990            0.0013            0.9954          2.7236          0.9825           1.3                 0.9895 
 
9.12  20  0            2.8803          0.9940            0.0669            0.9137        30.1230          0.9767           4.2                 0.9136 
9.12  20  15                   0.1446          0.9989            0.0020            0.9896          3.5166          0.9661           1.3                 0.9849 
9.12  20  30                   0.1076          0.9965            0.0014            0.9977          2.6832          0.9676           1.2                 0.9845        
9.12  20  45                   0.0882          0.9977            0.0011            0.9974          2.4329          0.9839           1.3                 0.9831 
 
2.41  30  0            2.1628          0.9842            0.0579            0.9701        20.3970          0.9802           1.1                 0.9633 
2.41  30  15                   0.2157          0.9593            0.0037            0.9952          4.1384          0.9824           0.8                 0.9948  
2.41  30  30                   0.1706          0.9299            0.0026            0.9952          3.4707          0.9903           0.8                 0.9888        
2.41  30  45                   0.1268          0.9385            0.0017            0.9876          2.5984          0.9885           0.7                 0.9950 
 
4.50  30  0            1.4122          0.9897            0.0279            0.9313        15.1810          0.9768           1.4                 0.9836 
4.50  30  15                   0.2107          0.9854            0.0050            0.9199          4.5702          0.9693           1.0                 0.9876  
4.50  30  30                   0.1603          0.9607            0.0024            0.9984          3.6219          0.9959           0.9                 0.9855        




 Table  13 (Continue) . Kinetic parameters  of naproxen sodium release from EC-coated HPMC matrix tablets 
 
         
EC coating       Opadry          HPMC         Zero order equation  First order equation          Higuchi  equation        Korsmayer- Peppas equation 
Level  (%)        concentration      content in          K0   R2                           K1          R2               KH           R2                    n             R2
            in EC coat ( % )     core tablet ( % )     ( % min-1 )   ( min-1 )       ( % min -1/2  ) 
         
5.78  30  0            2.0535          0.9796            0.0528            0.9512        23.8190          0.9769           2.9                 0.9755 
5.78  30  15                   0.1933          0.9907            0.0041            0.9258          4.8578          0.9799           1.0                 0.9934  
5.78  30  30                   0.1374          0.9747            0.0019            0.9964          3.2481          0.9919           0.9                 0.9891        
5.78  30  45                   0.1076          0.9741            0.0014            0.9970          2.6983          0.9983           0.9                 0.9872 
 
8.09  30  0            2.8076          0.9996            0.0625            0.9730        25.1260          0.9666           3.5                 0.9516 
8.09  30  15                   0.1753          0.9980            0.0028            0.9793          4.5464          0.9771           1.2                0.9838  
8.09  30  30                   0.1305          0.9923            0.0018            0.9953          2.9539          0.9585           1.1                 0.9819        




 3. Effects of EC coating  
 
3.1 Effects of EC coating on drug release  
 
3.1.1 EC coating with no water-soluble additive 
  
The release profiles of aspirin from the HPMC matrix tablets coated with 
different amounts of Surelease without any water-soluble component in 
the coating formulation, are shown in Figures 12 and 13.  
 
I t  was observed that for a poorly water-soluble drug like aspirin, EC 
coating of matrix tablets had a considerable impact on drug release rate 
(Figures 12 and 13). Application of EC coating led to significant decrease 
in aspirin release rate. The higher the quantity of EC coating, the slower 
was the aspirin release rate. Release constants K0  and  K1 were both 
inversely related to the EC coating quantity (Table 12).  
 
The marked effect of EC coat could be clearly observed in aspirin tablets 
without HPMC in the core. Compared to the uncoated tablets which 
released 100 % of the drug in less than 180 min (Figure 11), aspirin 
tablets coated with 1.78 % of EC layer released only 75 % of the drug into 
the dissolution medium within 180 min (Figure 12). When EC coating 
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Figure  12.  Effect of  different HPMC levels on aspirin release from matrix tablet with 
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Figure  13.  Effect of  different HPMC levels on aspirin release from matrix tablet with 
3.36% EC coating without Opadry.  () 0 %      () 10 %      (z) 15 %     ({) 20 %  
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 in the same time interval and less than 10 % in 8 h (Figure 13). Further 
increase in EC coating amount led to practically no release. The same 
trend was noticed in aspirin tablets with 10 %, 15 % and 20 % HPMC in 
the core.  
 
Difference in aspirin release rate due to variation in HPMC content 
decreased when EC coating was applied. When the coating reached a 
certain level,  the effect of HPMC content was insignificant (Figure 12 and 
13). The same result was seen from the K0  or K1 values at different HPMC 
contents (Table 12). At EC coating level of 1.78 % and 10 %, 15 % and 20 
% HPMC contents in the core, aspirin K0  values were 0.0618, 0.0552 and 
0.0408 respectively. Increasing EC coating level to 3.36 %, aspirin K0  
values decreased to 0.0118, 0.0132 and 0.0109 respectively. At 3.36 % 
coating level,  the amount of aspirin released within 8 h was close to 5 %, 
irrespective of the amount of HPMC in the matrix.  
  
The research work reported under Part I indicated that the drug release 
through HPMC matrix is mainly via diffusion. In reservoir type devices, 
when the controlling membrane is microporous, the release controlling 
step is also by diffusion. Drug release from such devices is a function of 
drug concentration in the device as well as the thickness of the diffusion 
barrier (Chen and Lee, 2002). EC coating without soluble additives had 
very poor water permeability, hence only limited amount of water could 
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 cross the coating barrier to enable dissolution of drug. A combination of 
EC coating with a poorly water-soluble drug like aspirin and a gel 
forming HPMC in the matrix core would dramatically retard drug release 
to very low rates. Therefore, drug release was low. When the EC coating 
level reached to certain amount, in this case around 4 %, the coat became 
almost completely impassable to water movement, hence, almost no drug 
release was observed. 
 
In comparison to aspirin, naproxen sodium is freely soluble in water.  The 
release profiles of naproxen sodium from the matrix tablets coated with 
different amounts of EC coating are shown in Figures 14-17. The release 
rate of naproxen sodium decreased as either EC coating level or HPMC 
content in the matrix was increased.  
 
Release of naproxen sodium was considerably faster than that of aspirin, 
even at much higher EC coating level and HPMC content. This was 
noticed both from the release profile (Figures 12-17) and release constant 
obtained (Tables 12 and 13). Without HPMC in the core, at 4.50 % of EC 
coating, over 90% of the naproxen sodium was released within 60 min 
(Figure 15), zero order release constant K0  was 2.1603. At 8.83 % EC 
coating, 8 h drug release from naproxen matrix containing 45 % HPMC 
still  exceeded 25 % (Figure 17)  with K0   value  at 0.0632. In comparison,  
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 less than 10 % of aspirin was released in 8 h, even at 3.36 % EC coating 
and K0  values were well below 0.025 regardless of HPMC content in the 
core (Table 12).  
 
I t  was also observed that when HPMC was not included in the core tablet, 
the ability of EC coat layer to sustain the release of naproxen was 
significantly less than that for aspirin. On increasing EC coating amount 
from 2.87 % to 8.83 %, the time taken to release 90 % naproxen sodium 
extended from about 45 min to 90 min only. This suggested that the 
control of the water-soluble drug release by only the application of EC 
coating was poor. 
 
 Varying HPMC content in the matrix demonstrated significant impact on 
release of naproxen sodium from EC coated tablet.  Increasing HPMC 
content in the core from 15 % to 45 % led to a decrease of more than 25 % 
of drug released with 8 h. The decrease was greater at  lower EC coating 
level.  At 2.87 %, 6.82 % and 8.83 % of EC coating, the decrease in 
amount of naproxen released due to increase of HPMC level was 35 %, 28 
% and 25 %, respectively (Figures 14-17).  The release constants in Table 
13 showed the same trend. At 2.87 % EC coating level,  increase of HPMC 
content from 15 % to 45 % led to a significant decrease of K0  value from 
0.1668 to 0.0951. Further increase in EC coating to 6.82 %, K0  value 













0 100 200 300 400 500











Figure  14.  Effect of  different HPMC levels on naproxen sodium release from matrix 
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Figure  15.  Effect of  different HPMC levels on naproxen sodium release from matrix 
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Figure  16.  Effect of  different HPMC levels on naproxen sodium release from matrix 
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Figure  17.  Effect of  different HPMC levels on naproxen sodium release from matrix 
tablet with 8.83 % EC coating without Opadry.  () 0 %   () 15 %   (z) 30 %  ({) 45 %   
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 Varying HPMC content in the matrix demonstrated significant impact on 
release of naproxen sodium from EC coated tablet.  Increasing HPMC 
content in the core from 15 % to 45 % led to a decrease of more than 25 % 
of drug released with 8 h. The decrease was greater at  lower EC coating 
level.  At 2.87 %, 6.82 % and 8.83 % of EC coating, the decrease in 
amount of naproxen released due to increase of HPMC level was 35 %, 28 
% and 25 %, respectively (Figures 14-17).  The release constant in Table 
13 showed the same trend. At 2.87 % EC coating level,  increase of HPMC 
content from 15 % to 45 % led to a significant decrease of K0  value from 
0.1668 to 0.0951. Further increase in EC coating to 6.82 %, K0  value 
decreased from 0.1376 to 0.0682. 
 
From the above results, i t  was found that with HPMC in the naproxen 
tablet,  both the HPMC content and EC coating level exerted significant 
contribution to the controlled release effect of the water-soluble drug. In 
comparison, without HPMC in the core, i t  was difficult to achieve 
controlled release effect by using only EC coating on the naproxen sodium 
tablets. The application of EC coating on HPMC matrix tablet offers an 
effective and precise approach to achieve the desired extended release for 
very water-soluble drugs. As demonstrated with the model drug, naproxen 
sodium, in the HPMC matrix, with core HPMC concentrations of 0 % to 
45 %, and EC coating level of 0 % to about 9 %, 8 h controlled release 
profiles could be adjusted from over 90 % to almost 30 %, therefore 
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 offering a wide range of formulation options. The release performance 
also suggested that the HPMC content in the core could be used as the key 
factor to modify drug release, with the EC coating for added leverage to 
more precise control of the release profile.    
 
3.1.2   EC coating with water-soluble additive  
 
I t  was noticed from the current work and earlier studies that the release 
profiles of poorly water–soluble aspirin and freely water-soluble naproxen 
sodium were affected by the constituent HPMC content in the core, as 
well as the thickness of EC coating applied. Compared to the freely water-
soluble drug, the release of the poorly water-soluble drug was more 
sensitive to changes in the thickness of EC coating.  
 
The amount of HPMC in the core formula can be precisely adjusted. 
However, the applied coating could vary slightly from batch-to-batch as 
slight changes in coating conditions could cause some variation in weight 
of coating applied. Consequently, very stringent control of the coating 
process is critical for minimal batch-to-batch variability and for 
reproducible drug release profiles. A method to minimize the problem is 
to add soluble channel - forming agent to the non - permeable EC coating  
as  it  would increase the porosity and permeability of the coating and 
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 consequently, decrease the sensitivity of release behaviour to small 
variations in the amount of coating applied. 
   
Opadry was chosen as the pore forming agent to be used and the effect of 
Opadry level in EC coating on aspirin release is depicted in Figures 18-21. 
For aspirin tablets, increase of Opadry level in the EC coating generally 
increased drug release.  However, the magnitude of increase was more 
noticeable when Opadry concentration in EC coat was 20 % and above.  
 
Adding 10 % Opadry to the EC coating did not contribute to significant 
difference in release performance over EC formulations without Opadry. 
At 4.06 % EC coating level,  amount of drug released within 8 h was still  
below 10 % irrespective of the amount of HPMC in the core (Figure 18). 
This release performance was comparable to that of 3.36 % EC coating 
without Opadry (Figure 13). When the EC coating level was increased to 
6.28 %, the amount of drug released within 8 h dropped below 5 % 
(Figure 19). As the release rate was low, there was litt le difference in 8 h 
aspirin release between tablets with different amounts of HPMC in the 
core.  
 
When the amount of Opadry in the EC coating was increased to 20 %, an 
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Figure  18.  Aspirin release from matrix tablet of different HPMC levels, coated with 4.06 
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Figure  19.  Aspirin release from matrix tablet of different HPMC levels, coated with 6.28 


































Figure 20.  Effects of  HPMC content in the matrix core and amount of EC coating with 





























Figure 21.  Effects of  HPMC content in the matrix core and amount of EC coating with 







 no or 10 % Opadry (Table 12). Aspirin release rate decreased markedly 
with increase of EC coating level or HPMC content in the core, when EC 
coating amount was below 6.09 % (Figure 20). However, i t  was clearly 
seen that the influence of HPMC content on aspirin release decreased as 
the coating weight increased. No significant difference in aspirin release 
rate was observed from tablets with different HPMC content when EC 
coating was about 6.09 % and above. However, the aspirin release rate 
still  decreased with increase in weight of EC coating amount to this level 
and above. 
 
When Opadry level in the EC coating was increased to 30 % (Figure 21), 
i t  was noticed that drug release was only slightly faster than at the 20 % 
level (Figure 20), when EC coating level was below 6 %. However, 
significant difference in release rate was obtained, when the EC coating 
level was about 6 % and above. 
 
Similar to EC coating with 20 % Opadry, both the HPMC content in the 
matrix and EC coating amount could be modified to offer a wider range of 
adjustment possibility to the controlled release performance, when Opadry 
level was increased to 30 %. Aspirin release rates varied from 92 % in 1 h 
to 32 % in 8 h at the HPMC / EC coat range studied. However, the 
sensitivity of aspirin release rate to EC coating level decreased as the 
concentration of the soluble additive was increased. 
107 
  
Release profiles for naproxen sodium at different Opadry concentration in 
EC coating are depicted in Figures 22-24. HPMC in the core still  had a 
big impact on sustaining naproxen sodium release rate. Without HPMC in 
the matrix core, more than 90 % of naproxen sodium was released within 
60 min, irrespective of the EC coating level and the Opadry concentration 
in the EC coat.  As soon as 15 % of HPMC was incorporated into the 
matrix core, even at very low EC coating level and high Opadry ratio,  
controlled release effect were able to extend to 8 h. It  was clearly seen 
that,  without HPMC in the core, variation in EC coating load and Opadry 
concentration had limited impact on drug release rate.   
 
Increasing Opadry level in the EC coating formulations increased the 
release rate of naproxen sodium. Influence of EC coating level and 
Opadry concentration were HPMC content dependent. When HPMC 
content was 15 % and above, increase of EC coating led to a noticeable 
decrease in drug release. Increase of Opadry level in the EC coating had 
the opposite effect on naproxen release. Significant difference in K0 value 
was observed.   
 

























% HPMC in the core
 
Figure 22.   Effects of HPMC content in the matrix core and amount of EC coating with 
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Figure 23.   Effects of HPMC content in the matrix core and amount of EC coating with 
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Figure 24.   Effects of HPMC content in the matrix core and amount of EC coating  with 







 Release rates of aspirin and naproxen sodium were affected by the HPMC 
content in the core, EC coating level and amount of Opadry in the EC 
coating. All the three formulation variables affected the release kinetics 
of water-soluble naproxen sodium and poorly water-soluble aspirin 
(Tables 12 - 13).   
 
Increase of EC coat thickness generally changed the release kinetics of 
aspirin to zero order. Aspirin tablets without EC coating followed Higuchi 
models for all  HPMC concentrations, as indicated by  n  values ranging 
from 0.6 - 0.8 (Table 12). However, tablets without HPMC followed zero 
order kinetics. With 1.78 % EC coating, aspirin tablets with 10 % to 20 % 
HPMC demonstrated best fit  with the zero order model.  The n  values for 
the tablets with 10 %, 15 % and 20 % HPMC in the core were 1.1, 0.9 and 
1.0 respectively, further indicating conformance to zero release model. 
When EC coating level was raised to 3.36 %, release characteristics all  
fi t ted the zero order model well with n  values ranging from 1.2 to 1.5. 
 
The above trends were in agreement with those observed in other studies 
which used diphenhydramine hydrochloride as a model drug in 
microcapsules coated with EC (Opota et al .,  1999). It  was found that the n  
value of diphenhydramine hydrochloride release increased from 0.70 to 
0.97 as EC coating weight increased. This suggested that release kinetics 
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 were originally non-Fickian, but approached Fickian diffusion at higher 
coating levels,  similar to the findings in this study.  
 
The impact of soluble additive in the EC coating on drug release was 
dependent on the proportion of soluble additive in the coating and 
thickness of EC coating layer. It  was clearly noticed that as the soluble 
additive level increased in the EC coating, higher EC coating quantity was 
needed in order to maintain zero order kinetics. When EC coating level  
was at 1.78 %, aspirin release kinetics generally followed zero order 
release with n  values ranging from 0.9 – 1.1, except tablets without 
HPMC in the core. However, at  similar EC coating level, adding 20 % 
Opadry to the EC coating changed the release kinetics of aspirin tablet 
from zero to first  order. The trend of decreasing n  value was noticed. The 
impact of soluble additive diminished when the coating level was 
increased to 3.79 % and above, with aspirin release kinetics reverting 
back to zero order. When Opadry concentration was further increased to 
30 %, 3.71 % of EC coating level was unable to produce a coating of 
sufficient integrity to provide constant release kinetics and aspirin release 
still  followed first order kinetics. Only when the level of EC coating 
increased to 5.78 % and above, the release kinetics reverted back to zero 
order. An increase in n  value from below 0.9 to above 1.0 was noted when 
the release kinetics changed.  
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 As seen for aspirin, the level of coat applied and the incorporation of 
soluble additive also affected the release kinetics of naproxen sodium. 
However, the relative extent of the effect was quantitatively dissimilar.   
 
Increased EC coating level could lead to change in the naproxen sodium 
release kinetics from first  order to zero order. It  was clearly observed that,  
when EC coating level was below 3 %, naproxen sodium release kinetics 
varied due to the differences in Opadry concentration in EC coating and 
HPMC content in the core. However, when EC coating level was above 
8.0 %, naproxen sodium release followed zero order kinetics irrespective 
of Opadry level and HPMC content.  
 
Effect of Opadry ratio on drug release kinetics was dependent on EC 
coating thickness and HPMC content. Without Opadry in EC coat,  release 
of naproxen sodium at all  coating levels investigated followed the zero 
order model when HPMC concentration in the core was 15 % and above. 
Increasing Opadry concentration in EC coat to 10 % changed the release 
kinetic model. At 2.65 % EC coating level,  release of naproxen sodium 
from matrix tablets changed to first  order kinetics. However, increasing 
EC coating level to 5.45 % and above reverted release kinetics to zero 
order,  irrespective of the HPMC content in the core. 
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 Similarly, when Opadry level was increased to 20 % and 30 %, EC coating 
level had to be above 5.44 % to maintain the zero order release model.  
 
The above phenomenon was in agreement with the findings of other 
workers. Studies using a model system based on EC coated beads 
containing phenylpropanolamine, with aqueous solubility in water of 40 g 
/  100 ml, demonstrated that drug release followed zero order kinetics 
(Ozturk et al . ,  1990).  Research using diphenhydramine hydrochloride 
microgranules coated with aqueous EC dispersion showed an n value 
increasing from 0.7 to 1.0 as the EC coating level increased from 6 % to 
12 %. Release kinetics were non-Fickian first order at lower EC coating 
level,  but approached zero order Fickian diffusion at higher coating levels 
( Opota et al. ,1999). 
 
In the present study, EC coat application actually suppressed drug release 
in the initial several hours. The degree of suppression was dependent on 
the coat thickness, soluble additive ratio in the coating formulation, and 
solubility of drug. When comparing differences in the release curves of 
systems conforming to Higuchi, first order or zero order models, the 
biggest differences observed were during the initial one third of the 
release profile. The Higuchi model showed the greatest non-linearity, 
followed by first  order, and then by zero order. Uncoated matrix tablets 
exhibited Higuchi release kinetics. Application of EC coating increased 
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 the linearity of the release curve, indicating conversion of release kinetics 
to first  order or zero order. As the EC coating level increased, the release 
pattern followed first order and eventually zero order kinetics.  Increasing 
the water-soluble additive had the opposite effect. As the ratio of soluble 
additive to EC polymer increased, the release curve reverted from zero 
order to first  order or Higuchi kinetics.   
 
I t  was observed that the matrix tablet cores which contained HPMC 
swelled when they came into contact with the dissolution fluid. At low EC 
coating load or when EC coat had high soluble additive level,  the HPMC 
swelling strength exceeded the strength of the EC layer, resulting in 
rupture of the coat in the weakest region at the tablet edge. As the 
dissolution run continued, the EC layer eventually peeled away from the 
tablet surface. This observation showed that the coating only remained 
effective during the initial few hours of the drug release profile, after 
which drug release was dependant on the properties of the core tablet 
matrix. At higher coating weight, the greater strength of the thicker coat 
enabled it  to withstand the swelling force of the core and the coat 
remained intact throughout the dissolution period. In this situation, the 




 Previous investigations showed that two components were possibly 
contributing to the zero order release mechanism of EC coated pellets.   
One of these was the osmotic force through aqueous pores, while the other 
was the diffusion force through the continuous polymer phase and aqueous 
pores  (Ozturk et al,  1990). These contributed to drug release 
simultaneously. A plot of release rate vs.  osmotic pressure revealed an 
inverse linear relationship with a non-zero intercept. The steep 
dependency of release rate on osmotic pressure suggested that osmotically 
driven release is a major component, while the non-zero intercept 
indicated some contribution from diffusion mechanisms. Drug release rate 
(dm/dt) at the steady state could be expressed in terms of these two 
components by the following equation (Ozturk et al,  1990): 
 
 dm/dt = (AS/h)Lpσ∆π  + PAS/h       (16) 
 
where dm/dt  is equal to K0 ,  A  is the surface area of the dosage form, h  is 
the thickness of the coating film, S  is the drug solubility, Lp  is the 
hydraulic permeability of the coating film, σ  is the reflection coefficient, 
∆π  is the osmotic pressure difference across the coating film, and P  is the 





 4. Mathematical relationship of drug release constant K0  with HPMC 
levels in the EC coated matrix tablets  
 
Drug release from the EC coated naproxen sodium matrix tablets generally 
fitted best to zero order kinetics. Therefore K0  values were used for 
evaluation. When the zero order constant K0  of different coating 
formulations at different coating levels was plotted against the HPMC 
content in the tablet core, a linear relationship (R2  > 0.99) was obtained in 
most cases (Figures 25-28). The relationship could be expressed as 
follows: 
 
K0 = - a  X  CH P M C  +  b      (17) 
 
where CH P M C  refers to the HPMC concentration in the matrix tablet core 
and a ,  b  are constants. The results of a, b  and R2  value at different EC 
coating amount and Opadry level are shown in Table 14. From the 
experimental data, a  showed no direct relationship with the EC coating 
level,  as a  value for each coating formulation were very similar. However, 
b  values showed a clear relationship with EC coating level applied to the 
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Figure   25.  Correlation of K0 with HPMC content in the naproxen sodium matrix core at 
different EC coating levels, without Opadry. () 2.87 % EC coat  () 4.50 % EC coat   
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Figure  26. Correlation of K0 with HPMC content in the naproxen sodium matrix core at 
different EC coating levels, with 10 % Opadry. () 2.65 % EC coat  () 5.45 % EC coat   
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Figure  27.  Correlation of K0 with HPMC content in the naproxen sodium matrix core at 
different EC coating levels, with 20 % Opadry. () 2.91 % EC coat  () 5.44 % EC coat   
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Figure  28. Correlation of K0 with HPMC content in the naproxen sodium matrix core at 
different EC coating levels, with 30 % Opadry. () 2.41 % EC coat  () 4.50 % EC coat   





Table 14.  Relationship of K0  value of naproxen sodium tablet with HPMC 
content in the tablet core, at different EC coating and Opadry levels  
 
 
EC coating level 
(%) 
 
    




    
     a value 
    
    b value  
    
   R2
 
  2.87 
       
     0 
      
     0.0024 
     
    0.2010 
     
  0.9939   
 
  4.50 
       
     0 
      
     0.0022 
     
    0.1900 
     
  0.9998  
 
  6.82 
 
     0  
 
     0.0023 
 
    0.1750 
 
  0.9822 
 
  8.83 
 
     0 
 
     0.0022 
 
    0.1635 
 
  0.9930 
 
  2.65 
     
     10 
 
     0.0023 
 
    0.2098 
 
  0.9993 
 
  5.45 
 
     10 
 
     0.0022 
 
    0.1832 
 
  0.9882 
 
  6.68 
 
     10 
 
     0.0024 
 
    0.1795 
 
  0.9854 
 
  9.26 
 
     10 
 
     0.0022 
 
    0.1735 
 
  0.9999 
 
  2.91 
 
     20 
 
     0.0026 
 
    0.2381 
 
  0.9901 
 
  5.44 
 
     20 
 
     0.0023 
 
    0.2182 
 
  0.9998 
 
  6.58 
 
     20 
 
     0.0025 
 
    0.2094 
 
  1.0000 
 
  9.12 
 
     20 
 
     0.0019 
 
    0.1699 
 
  0.9686 
 
  2.41 
 
     30 
 
     0.0030 
 
    0.2599 
 
  0.9999 
 
  4.50 
 
     30 
 
     0.0030 
 
    0.2530 
 
  0.9937 
 
  5.78 
 
     30 
 
     0.0029 
 
    0.2318 
 
  0.9700 
 
  8.09 
 
     30 
 
     0.0027 
 
    0.2135 
 




 For a poorly water-soluble drug such as aspirin, a linear relationship was 
not observed between K0  and HPMC content in the tablet core. Neither 


















 V. Conclusion 
 
In monolithic matrix system, particle size properties of the controlled 
release polymer, HPMC, had significant impact on drug release 
performance.  
 
The rate of aspirin released from the matrix tablet generally decreased as 
the mean particle size of HPMC was reduced. The mean particle size of 
113 µm for HPMC particles was identified as a critical criterion for 
obtaining consistent drug release profile. When mean particle size of 
HPMC was greater than 113 µm, a markedly higher rate of drug release 
was observed. In contrast ,  less significant effects on release rate were 
observed when using HPMC powder of mean particle size 113 µm or 
smaller.   
 
Drug release mechanism was affected by HPMC mean particle size and 
concentration. When HPMC mean particle size was 113 µm or smaller, 
dissolution profiles gave a better fi t  with first  order kinetics, indicating a 
combination of both erosion and diffusion as the controlling factors for 
drug release from matrix tablet.  Drug release mechanism changed as 
HPMC mean particle size was 180 µm and above. 
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 Polymer powders consisting of particles of similar mean particle sizes but 
of different size distributions were found to influence drug release rate 
but not the drug release mechanism. Drug release from both the sieved 
and unsieved polymer powders fitted better to first  order release model. 
However, a difference in K1  value was observed when HPMC content was 
below 20 %. 
 
HPMC content was identified to be very important because of its 
influence on the effects of HPMC particle size and size distribution. 
Maintaining HPMC content above 20 % was helpful in developing a 
robust matrix system. 
 
Drug release constant was proportionally related to polymer mean particle 
size and relative number of polymer particles in the matrix system, as 
demonstrated by the following equation: 
 
 K 1 =  d/ (Np o l y m e r  X Pp o l y m e r)1 / 3  + a      
 
where Np ol y m e r  refers to the relative number of polymer particles in the 
formula, Pp ol y m er  is the mean particle size of the polymer powder and d  is 
a constant indicating sensitivity of the matrix system to changes in 
particle size and polymer quantity. The value, a ,  is a release retarding 
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 constant. This result  can be used to eliminating the negative effects of 
varied polymer particle properties on matrix performance. 
 
The release performance of water-soluble naproxen sodium and sparingly 
soluble aspirin from EC coated HPMC matrix tablets was investigated. 
Drug release rate decreased as HPMC content in the matrix core creased. 
Higher EC coating level led to lower drug release rate as the membrane 
permeability was decreased. Increase of Opadry concentration in EC 
coating increased drug release rate due to increased porosity and diffusion 
channels. The release of aspirin was more sensitive to EC coating level,  
while that of naproxen sodium was influenced more significantly by 
HPMC content in the core.  
 
Application of EC coating to matrix tablets was found to suppress drug 
release rate during the initial several hours, the magnitude of suppression 
was dependent on the coating thickness and soluble additive 
concentration. Release kinetics normally followed the zero order model at 
higher EC coating levels. At lower EC coating levels, increase of Opadry 
concentration in the EC coating changed the release kinetics from zero 




 K0  obtained from naproxen sodium tablets coated with different EC 
coating formulations and different coating load had a linear relationship 
with HPMC content in the core, which was expressed in the following 
equation. This relationship was not found with aspirin tablets.  
 
K0 = - a  X  CH P M C  +  b       
 
where CH P M C  refers to the HPMC concentration in the matrix tablet core 
and a ,  b  are constants. The constant,  a  showed no direct relationship with 
the EC coating level,  as a  value for each coating formulation were very 
similar.  However, b  values showed a clear relationship with EC coating 
level applied to the matrix tablets and the b  values decreased considerably 
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